 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
ADalimumab Vs. conventional 
ImmunoS uppr Ession for uveitis 
(ADVISE)  
Trial  
 
  
 
 
 
  
 
 
 Protocol version 1. 3 
12 October 2020  
 
 
 
ClinicalTrials.gov identifier:  [STUDY_ID_REMOVED]   
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Contents │ 2 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  ADVISE Protocol 1. 3 (12 Oct 2020 ) 
Contents  
Contents  ............................................................................................................................... 2  
Document revision hist ory .................................................................................................... 5  
Document distribution ..........................................................................................................10  
Abstract  ...............................................................................................................................11 
1. Introduction  ...................................................................................................................12 
1.1 Title ......................................................................................................................12 
1.2 IND .......................................................................................................................12 
1.3 Financial sponsor  ................................................................................................. 12 
1.4 Resource centers  ................................................................................................. 12 
1.5 Clinical centers  .....................................................................................................13 
1.6 Additional Support  ................................................................................................13 
1.7 Backgr ound and significance ................................................................................14 
1.8 Preliminary studies  ...............................................................................................17 
Table 1.  Distribution of uveitic diseases in the MUST Trial  .................................................18 
1.9 Rationale for trial ..................................................................................................18 
2. Objective and study hypothesis  .....................................................................................19 
2.1 Objective and specific aims  ..................................................................................19 
2.2 Hypotheses  ..........................................................................................................19 
3. Design  ...........................................................................................................................20 
3.1 Design elements  ...................................................................................................20 
3.2 Randomized treatment arms  ................................................................................20 
3.3 Trial schematic  .....................................................................................................21 
3.4 Outcomes  .............................................................................................................22 
3.4.1  Primary outcom e .........................................................................................22 
3.4.2  Secondary outcomes  ...................................................................................22 
3.4.3  Disease -specific assessment to permit ascertainment of outcomes pertaining 
to activity of uveitis  .......................................................................................23 
3.5 Eligibility criteria  ....................................................................................................25 
3.6 Stratification and randomization ............................................................................26 
3.7 Data collection schedule .......................................................................................27 
Table 2.  Visit and examination schedule  ................................ ............................................28 
4. Treatment  ......................................................................................................................29 
4.1 Overview  ..............................................................................................................29 
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Contents │ 3 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  4.2 Systemic corticosteroids  .......................................................................................29 
4.2.1  Initial prednisone dose  .................................................................................30 
Table 3.  Initial prednisone dosing summary  .......................................................................31 
4.2.2  Prednisone tapering schedule and goals  .....................................................31 
Table 4.  Prednisone tapering schedule  ..............................................................................32 
4.3 Corticosteroid -sparing drugs  .................................................................................33 
4.3.1  Adalimumab treatment group  .......................................................................33 
4.3.2  Conventional immunosuppression treatment group .....................................33 
Table 5.  Conventional immunosuppressive drugs in the ADVISE Trial  ...............................34 
4.4 Advancement of immunosuppressive treatment ...................................................35 
4.5 Management of uveitis reactivation ......................................................................35 
Table 6.  Reactivation management guidelines  ................................................................... 37 
4.6 Monitoring for toxicity of immunosuppressive drugs ..............................................38 
4.7 Discontinuation of treatment  within the assigned treatment arm  ...........................38 
4.7.1  Discontinuation for toxicity  ...........................................................................38 
4.7.2  Discontinuation for pregnancy  ..................................................................... 39 
4.8 Ancillary therapy  ...................................................................................................39 
4.8.1  Regional corticosteroid Injections  ................................................................39 
4.8.2  Topical corticosteroids  .................................................................................39 
4.8.3  Non-corticosteroid ophthalmic medications  ..................................................39 
4.8.4  Systemic medications other than corticosteroids and immunosuppressive 
drugs  ...........................................................................................................39 
4.8.5  Treatment monitoring ...................................................................................40 
5. Study treatment procurement  ........................................................................................41 
6. Possible side effects and complications of study treatments  .........................................42 
Table 7.  Potential risks of therapy  ......................................................................................45 
7. Safety reporting of adverse events  ................................................................................47 
7.1 Adverse events  .....................................................................................................47 
7.2 Serious adverse events  ........................................................................................47 
8. Sample size and statistical methods  ..............................................................................48 
8.1 Hypotheses  ..........................................................................................................48 
8.2 Sample size and power calculations  .....................................................................48  
8.
3 Statistical analysis plan ........................................................................................49 
9. Regulatory and ethical issues  ........................................................................................50 
9.1 Recruitment and informed consent procedures  ....................................................50 
ADVISE PROTOCOL 1.3  (12 OCT 2020)   Contents │ 4 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  9.2 IRB/Protection of human subjects  .........................................................................51 
9.3 Data and Safety Monitoring Committee  ................................................................51 
10. Study implementation ....................................................................................................52 
10.1  Study organization ................................................................................................52 
10.1.1  Characteristics of target population and recruitment strategies  ....................52 
10.2  Quality assurance  ................................................................................................. 52 
10.2.1  Medical Therapy Quality Assurance Committee  ..........................................52 
10.2.2  Visual Function Quality Assurance Committee  ............................................53 
References  ..........................................................................................................................54 
 
Table of Tables  
Table 1.  Distribution of uveitic diseases in the MUST Trial  .......................................................18 
Table 2.  Visit and examination schedule  ..................................................................................28 
Table 3.  Initial prednisone dosing summary  .............................................................................31 
Table 4.  Prednisone tapering schedule  ....................................................................................32 
Table 5.  Conventional immunosuppressive drugs in the ADVISE Trial  14,21 ..............................34 
Table 6.  Reactivation management guidelines  .........................................................................37 
Table 7.  Potential risks of therapy  ............................................................................................ 45 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Document revision history │ 5 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
Document revision history  
 
Version 1.0 (6 Feb 2019)   
• Cover:  added ClinicalTrials.gov identifier  
 
• Table 2:   Visit and Examination Schedule: Added height at month zero (baseline)  
 
• Table 4:  Prednisone tapering schedule: 7.5 mg/day hold period modified from “ Hold for 
4 weeks” to “Hold until two study visits ≥4 weeks (28 days) apart have occurred* 
*Note:  This may  involve maintaining the dose for more than two consecutive study visits if they 
occur <28 days apart.  
 
• Corrected typographical errors, e.g., <7.5 mg/day prednisone to  ≤ 7.5 mg/day in section 
2.2 (secondary hypotheses #1 and 4.2.2 in description of primary  outcome ) 
 
Version 1.1 (31 Oct  2019)  
• Section 1.2 IND  
-  Added clarif ication  that the IND covers the conventional immunosuppr essive 
drugs used in the trial  
 
• Section 1.4 Resource centers  
- Updated the location of  Study Chairman’s Office (as of 1 Aug 2019)  
 
• Section 3.1 Design elements  
- Corrected  time points for masked assessment of photographic images and OCT 
by the RC (graders masked)  
 All patients  
∙ OCT at baseline, 3, 6, and 12 months  
∙ Retinal color photographs at baseline, 6 and 12 months  
 Disease -specific ima ge or OCT, as applicable, at baseline, 1, 3, 6, and 12 
months  
 
• Section 3.2.1 Randomized treatment arms  (Adalimumab)  
- R emoved adalimumab dosing schedule for adolescents <30 kg ( they are now 
excluded from the study ) 
 
• Section 3.4.3  Disease -specific assessment to permit ascertainment of outcomes 
pertaining to ac tivity of uveitis  
- For birdshot chorioretinitis - corrected Humphrey 24- 2 to 30 -2 
- Removed “other conditions with exudative detachment(s)” from list of conditions 
for which OCT will be used to determine resolution of exudative detachments.   
Vogt-Koyanagi -Harada early disease is the only condition that will be monitored  
in that manner . 
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Document revision history │ 6 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  • Section 3.5 eligibility criteria  
- Added inclusion criterion: Weight 30 kg (66 lbs) or greater  
- Added exclusion criterion:  Any of the following baseline lab values  
a. White blood count <3500 cells per microliter  
b. Platelets <100,000 per microliter  
c. Hematocrit <30%  
d. AST or ALT >1.5X upper limit normal value 
e. Serum creatinine >1.1X upper limit normal value 
- Expanded exclusion criterion “Multiple sclerosis’ to “Multiple sclerosis or other 
demyelinating disease” 
- Added clarification regarding MRI screening as italicized: For patients with 
anterior/intermediate or intermediate uveitis without systemic disease , abnormal 
magnetic resonance imaging (MRI) of the brain consistent with demyelinating 
disease  
- Added exclusion criterion:  Severe uncontrolled infection  
- Added exclusion criterion:  Moderate to severe heart failure (NYHA class III/IV  
- Added exclusion criterion:  Active malignancy  
- Expanded pregnancy exclusion and length of time birth control use required: 
For persons of child- bearing potential or impregnating potential, unwillingness to 
use appropriate birth control (abstinence, combination barrier and spermicide, hormonal, or intrauterine device) for the next  15 months or plans to become a 
biological parent within the next 15 months  
 
• Section 3.7 Data collection table  
- Added note for disease specific test  early -stage VKH,  – OCT:   
Ʌ OCT centered 
on fovea and additionally, as needed,  OCT centered to capture the area with 
greates t subretinal thickness  
- Removed other conditions with exudative detachment(s) from conditions for 
which OCT will be used to determine resolution of exudative detachments for determination of uveitis activity.   
- Added italicized clarification: Gadolinium enhanced MRI for patients with anterior/intermediate or  intermediate uveitis without  systemic disease  only 
- Corrected  parameter for automated perimetry with Humphrey SITA -fast 30 -2 
(previously 24- 2 in error) and P60. 
 
• Section 4. Treatment  
General modifications to section 4 and subparts:  
- Renamed section from Treatment schedule to Treatment  
- No essential changes  made; generally reworked of sections for clarification 
including  
 Clarification that study treatments should adhere to guidelines.  For situations not covered by guidelines, follow general study treatment 
principles and use best medical judgment 
 Specified  basic principles for study treatment  
 Clarified  that time points in treatm ent guidelines (e.g., 4 weeks) are 
targets and that variations due to scheduling of study visits is permitted 
and expected  
 
• Section 4.2.1  Initial prednisone dose  
- Revised Table 3:  Initial prednisone dosing summary  to include more detail  
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Document revision history │ 7 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
• Section 4.3.1 Adalimumab treatment group  
- Removed dosing protocol  for adolescent patients based on body weight  (i.e., 
different dosing protocols for adolescents < 30 kg vs those ≥30 kg for which 
dosing protocol is same as for adults). Only patients  ≥30 kg will be enrolled in 
trial, thus the  same dosing protocol will be used for all patients.  
- Changed reference for adolescent dosing  (previously referenced  Sycamore 
study)  
 
• Section 4.3.2 Conventional immunosuppression treatment group  
- Table 5:  Conventional immunosuppressive drugs in the ADVISE  Trial - revised 
footnote re:  timing of dose escalation for trac rolimus  from monthly to every 2 to 4 
weeks  
 
• Section 4.4 Advancement of immunosuppression – entire section was added 
 
• Section 4.5 Management of uveitis reactivation 
- Section reworked for reactivation for clarity with the addition of some details 
including specification of prednisone dose to be reinstated if uveitis reactivates after achieving cessation  
- Table 6.  Reactivation management guidelines  was revised to two tables, 6a and 
6b, for prednisone and i mmunosuppression, respectively  
 
• Section 9.1 Recruitment and informed consent 
- Added clarification that adolescent participants and parent or guardian will give 
written assent/consent according to the guidelines of the clinic’s governing IRB.  
- Changed reading  level of consent from 8
th grade level to 9th grade level  
 
• Section 10.2.2 Visual Function Quality Assurance Committee  
- Corrected Humphrey 24- 2 to 30-2 
 
• References  
- Removed: Ramanan AV, Dick AD, Jones AP, McKay A, Williamson P, 
Compeyrot -Lacassagne S, Hardwic k B, Hickey H, Hughes D, Woo P, Benton D, 
Edelsten C, Beresford M for the SYCAMORE Study Group.  Adalimumab plus 
methotrexate for uveitis in juvenile idiopathic arthritis.  N Engl J Med 
2017;376:1637 -46.  PMID:  28445959  
 
• Corrected  typographical and spelling errors throughout  
 
Version 1.2 (13 Dec 2019)  
• Section 3.1 Design elements, added: First patient enrolled in September 2019; the end of the trial (completion of follow -up of last patient enrolled) is expected to be February 
2023.  
 
• Section 3.5 Eligibility criteria  
− Added the following clarification to exclusion criterion Untreated active hepatits B 
or C infection: Active hepatitis B is defined as positive surface antigen; active 
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Document revision history │ 8 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  hepatitis C is defined as positive antibody and positiv e polymerase chain reaction 
(PCR)  
− Added exclusion:   Receipt of a live vaccine within past 30 days  
− Added exclusion:  Hypersensitivity to any of the study treatments or their 
excipients  
− For exclusion re: unwillingness to use birth control for persons of child -bearing or 
impregnating potential:  
 Changed time for use of birth control from 15 to 18 months  
 Added note  that combination barrier and spermicide should not be used 
by UK patients  
 
• Section 6. Possible side effects and complications of study treatment s 
Added medications that are prohibited during the trial for safety reasons:  
− Live vaccines  
− Substrates for the multidrug efflux transporter P -glycoprotein or the organic anion 
transporter proteins (OAT P), e.g., bosentan, dabigatran etexilate and aliskiren. 
− Products containing Hypericum perforatum (St John´s Wort) to avoid risk of 
interaction with tacrolimus (also added to tacrolimus entry in Table 7, Potential risks of therapy  
 
• Section 7.2 Serious adverse events:  Specified that UK clinics are required to report SAEs to the CC within 24 hours as to be compliant with EU/UK requirements.  Non -UK 
clinics have 72 hours to report SAEs to the CC.  
 
 
Version 1.3 (9 Oct 2020 ) 
• Section 3.7 Data collection schedule, Table 1 Visit and examination schedule 
− Added clarification to footnote:  chemistry panel including serum glucose  
− Added clarification: Screening P -60 test  
 
• Section 3.4.3 Disease -specific assessment to permit ascertainment of outcomes 
pertaining to activity of uveitis : Birdshot chorioretinitis – Corrected Humphry settings by 
changing 24 -2 to 30-2 in two places as missed during  
 
• Section 4.2 Systemic corticosteroids :  Corrected typo in first paragraph, maximum dose 
of prednisone; changed 60 mg/kg/day to 60 mg/day  
 • Section 4.2.1 Initial prednisone dose, Table 3. Initial prednisone dosing summary :   
Added text (as italicized) to scenarios “substantively improved “and “not controlled” in 
last column: Taper but not below 7.5 mg/day until inactive  
 
• Section 4.5 Management of uveitis reactivation, Table 6a, Reactivation guidelines – 
Prednisone:  Added italicized text for clarification for scenario, Reactivation during 
prednisone taper  -Not controlled, 4 weeks after prednisone increase:  Taper  but not 
below 7.5 mg/day  until inactive  
ADVISE PROTOCOL 1.3 (1 2 OCT 2020)   Document revision history │ 9 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
• Section 4.8.1 Regional corticosteroid Injections :  Revised to make the intravitreal 
dexamethasone pellet an acceptable ancillary treatments for macular edema.  
Previously treatment with the dexamethasone pellet  was excluded because, at the time 
the protocol was written, the expected duration of the treatment effect was about 5 
months based on data from the HURON Trial.  However, in the POINT Trial we found 
the treatment effect to be shorter, about the same as Tr iesence, approximately 3 
months.  
 
• Section 4.8.2 Topical corticosteroids  
− Corrected typo in the concentration of difluprednate from 0.005 to 0.05  
− In 3rd bullet, clarified the maintenance dose permitted for each of three drugs  
 
• References:  Added reference 74 (results of POINT Trial)   
 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Document distribution │ 10 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Document distribution 
 
Version  Version date  Distribution  Distribution date  
1.0 26 Oct 2018  Abbvie   29 Oct 2018  
  JHSPH IRB  06 Nov 2018  
    
 19 Dec 2018  JHSPH IRB  28 Dec 2018  
  Clinical Centers  24 Jan 2019 (PPM 1)  
  FDA 06 Feb 2019  
    
 06 Feb 2019 * JHSPH IRB  8 Feb 2019  
    
1.0 Canada† 
 30 Oct 2019  
 Health Canada  
MUHC  clinical center  30 Oct 2019  
04 Nov 2019  
    
1.0 UK‡ 
 
 
 22 Nov 2019  
 
 
 UK Medicines and 
Healthcare products Regulatory Agency 
(MHRA)  28 Nov 2019  
  
 
    
1.1 31 Oct 2019 * JHSPH IRB  5 Nov 2019  
    
    
1.2 13 Dec 2019  JHSPH IRB  16 Dec2019  
  Clinical Centers  31 Jan 2020 (PPM 21) \ 
  FDA 05 Jun 2020  
  Health Canada  12 Mar 2020  
    
1.3 12 Oct 2020    
 
* Interim v ersions, not distributed to clinical centers 
 
† Interim Canadian version only  (19 Dec 2018 to 30 Oct 2019) :  Revisions r equested by Health Canada 
were made to this Canadian- only version . The following exclusion criteria were added: severe 
uncontrolled infection; moderate to severe heart failure (NYHA class III/IV); active malignancy . 
Subsequently  these revisions  were incorporated into protocol version 1.2 (13 Dec 2019 . 
 
‡ Interim UK  only version (19 Dec 2019 to 22 Nov):  Revisions requested by the UK Medicines and 
Healthcare products Regulatory Agency (MHRA)  were ma de to this UK  versio n.  These are the 
substantive changes made to exclusion criteria:  clarification of lab results for active hepatitis B and C 
infections; added exclusion for specificed baseline lab values; added exclusions for severe uncontrolled 
infection, live vaccine within past 30 days,hypersensitivity to and study treatments or excipients; revision of pregnancy criteria to include persons of child- bearing or impregnating potential.  Added medications 
not to be used during the trial (end of section 6.).  Subsequently these revisions  were incorporated into 
protocol version 1.2 (13 Dec 2019) .
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)   Abstract │ 11 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Abstract  
 
 
The uveitides are a collection of diseases characterized by intraocular inflammation.  Collectively, they are the 5
th leading cause of blindness in the US, and the estimated cost of 
treating them is similar to that of treating diabetic retinopathy.  Non- infectious intermediate, 
posterior, and panuveitides have the highest rates of visual loss and typically are treated wi th 
oral corticosteroids and immunosuppression.  The Multicenter Uveitis Steroid Treatment 
(MUST) Trial (a randomized, comparative effectiveness trial, which compared 2 treatment 
paradigms for these diseases, systemic therapy with corticosteroids and immunosuppression vs. regional therapy [the fluocinolone acetonide implant]), and Follow -up Study demonstrated 
the superiority of the systemic approach to the regional ocular approach in terms of long- term 
visual outcomes with essentially no increase in systemic  side effects in the systemic group.  
One key to systemic therapy’s success was the use of systemic immunosuppression in 88% of participants, coupled with tapering the prednisone to < 7.5 mg/day, a relatively safe dose.  Non-
alklyating agents are typically the first choice and the most often  used are azathioprine, 
methotrexate, mycophenolate, cyclosporine, and tacrolimus.  The alkylating agents, cyclophosphamide and chlorambucil, are used less often because of concerns about potential 
increased malignancy risk. Data from the Systemic Immunosuppressive Therapy for Eye 
Diseases (SITE) Cohort Study suggest that each of the conventional, non- alkylating agent 
immunosuppressive drugs is effective in controlling the inflammation while permitting tapering prednisone in ~40- 55% of patients; hence combination therapy often is needed.  Furthermore, 
minimizing the daily dose of prednisone is important, as the risk of cardiovascular disease and 
mortality increase with the cumulative dose of oral corticosteroids. In June 2016, the fully -
human, anti -TNF-α monoclonal antibody, adalimumab, was approved by the US Food and Drug 
Administration (FDA) for the treatment of uveitis.  Anti- TNF-α monoclonal antibody therapy has 
revolutionized the management of the rheumatic diseases largely due to its superior efficacy 
compared to conventional Disease Modifying Anti -Rheumatic Drugs.  Data from VISUAL III, the 
extension of the two phase 3 trials that led to the FDA approval of adalimumab for the treatment of uveitis, suggest that adalimumab may be superior to conventional immunosuppression, as 
~75% of participants had controlled inflammation with prednisone doses <5 mg/day.  The 
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, 
comparative effectiveness trial comparing adalimumab to conventional agent 
immunosuppression for patients with non- infectious, intermediate, posterior, and panuveitides.  
The primary outcome is the ability to successfully taper prednisone to < 7.5 mg/day by 6 months 
after random ization while maintaining control of the inflammation.  Secondary outcomes include 
prednisone discontinuation by 1 year, visual acuity, and complications of uveitis and its treatment.  
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 12 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  1. Introduction  
 
1.1 Title 
ADalimumab Vs. conventional I mmunoS upprEssion for corticosteroid- sparing for uveitis  
(ADVISE) Trial  
 
 
1.2 IND  
ADVISE is being  conducted under IND 132532 held by Jennifer E. Thorne, MD, PhD, the Study 
Medical Safety Officer, for the Coordinating Center .  The product  named in the IND is Humira 
(adalimumab) ; the IND covers the conventional immunosuppressive drugs  used in ADVISE (i.e., 
azathioprine, methotrexate, mycophenolate, cyclosporine, tacrolimus).  
Adalimumab was FDA approved for the treatment of non -infectious intermediate, posterior, and 
panuveitides in adult patients  in 2016 and in pediatric  patients 2 years of age and older  in 2018 .  
In 2016, prior to FDA approval of adalimumab for treatment of uveitis in pedi atric patients , the 
Coordinating Center submitted an IND exemption request to the FDA for use of adalimumab in 
adolescent patients (13 to <18 years of age) for the ADVISE Trial.  In response, t he FDA 
determined that use of adalimumab for the treatment of non -infectious intermediate, posterior, 
and panuveitides in adolescent patients in ADVISE does not increase risk for these patients as  
the drug was  approved for treatment of pediatric patients for other indications.  However, 
although conventional immunosuppressive drugs are the standard  approach and in widespread 
use, these drugs are not FDA approved for treatment of non -infectious intermediate, posterior, 
and panuveitides, and therefore an IND is required.    
   
1.3 Financial sponsor   
ADVISE is funded  by the National Eye Institute  through linked UG1 grants to the Study  
Chair man’s Office  (CO) , the Coordi nating Center  (CC) , and the Reading Center  (RC) .  Clinical 
centers are funded through sub- agreements with the CC.  
  
1.4 Resource centers  
 
Center   
Director /Co-Directors  
  
Study  Chairman’s Office  
Johns Hopkins Bloomberg School of Public Health, Baltimore  
 
Coordinating Center   
Douglas Jabs, MD, MBA  
 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD  
 Janet Holbrook, PhD, MPH  
Elizabeth Sugar, PhD  
Reading Center   
University of Wisconsin at Madison, Madison, WI  Michael Altaweel, MD  
 
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 13 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  1.5 C linical centers  
Clinical centers will be  located in the United States, the United Kingdom, Australia, and Canada. 
A list of participating clinical centers is included in the ADVISE Manual of Procedures.    
 
1.6 Additional Support  
AbbVie (Chicago, IL)  will donate  adalimumab  for the trial.  
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 14 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
1.7 Background and significance 
The uveitides are a collection of diseases characterized by intraocular inflammation.1  In the 
United States (US), the uveitides collectively are the 5th leading cause of blindness and are 
responsible for an estimated 30,000 new cases of blindness annually.2  They cause an 
estimated 2.8% to 10% of blindness in the working age population. 2,3,4,5,6 The cost of treating 
the uveitides is comparable to that of treating diabetic retinopathy.7  In addition to the estimated 
direct cost of treatment, there are substantial indirect costs, as treatment  of the more severe 
uveitides is labor intensive, typically requiring patient visits every 4- 6 weeks for at least several 
years. The estimated incidence of uveitis is 17- 54/100,000/year, and the estimated prevalence 
of active uveitis is 115- 204/100,000. 3,5 In 1993, Research to Prevent Blindness estimated the 
prevalence as 1% of the US population.8 Because  the uveitides affect all ages, including 
children and working- age adults, the potential years of vision lost and economic impact per case 
exceed that of age- related diseases, such as cataract and age -related macular degeneration.  
Hence research into improving the outcomes of management of these diseases is critical for 
lessening their burden of visual impairment and blindness. For these reasons, improving 
methods for the treatment of the uveitides is one of the strategic goals of the National Plan for 
Eye and Vision Research (htpps://nei.nih.gov/strategicplanning/np_retinal, accessed 30 August 
2016).   
 
The uveitides typically are classified by the primary site of inflammation as anterior, 
intermediate, posterior, or panuveitis.1,9  Although anterior uveitides are somewhat more 
common than intermediate, posterior, or panuveitides, the incidences of visual impairment (worse than 20/40) and blindness (20/200 or worse) are far greater among intermediate, 
posterior and panuveitides.  For posterior and panuveitides, the rates of visual impairment and 
blindness are nearly 3- fold greater than those seen with anterior uveitides.
10 Hence 
intermediate, posterior, and panuveitides cause a disproportionately large share of visual 
impairment and blindness from uveitis.  Uveitides may be infectious or non -infectious; the 
majority of cases in the US are non -infectious. 1,9 Uveitides  also may be monophasic and 
spontaneously -remitting, recurrent acute (episodic with periods of inactive disease off treatment 
between attacks), or chronic (with prompt relapse upon discontinuation of treatment and the need for chronic suppression).  The la rge majority of cases of intermediate, posterior, and 
panuveitides are chronic and require long- term, possibly life -long, therapy. 1
,9  Although some 
cases of intermediate uveitis may be observed or treated intermittently,11,12 many cases of 
intermediate uveitis and nearly all posterior and panuveitides require treatment with oral 
corticosteroids and immunosuppression.13,14,15,16 Immunosuppressive drug treatment provides 
superior outcomes to corticosteroids alone for several specific uveitic diseases.15,17,18,19,20  In the 
MUST Trial and Follow -up Study, systemic therapy with oral corticosteroids and 
immunosuppression produced superior visual acuity outcomes at 7 years of follow -up compared 
to regional therapy with the fluocinolone acetonide intraocular implant, in part due to the variable duration of effect of regional therapies and the uveitis reactivation that occurs prior to re-implantation.
15  Furthermore, the systemic approach had a significantly lower risk of ocular 
adverse effects (primarily cataract and ocular hypertension/glaucoma) with no significantly 
increased risk of syst emic side effects, except for a greater use of antibiotics for 
infections.15,21,22,23,24   Sustained, drug -free, remissions (defined as inactive disease off all 
treatment) occasionally are possible for some chronic uveitides managed with 
immunosuppression, but they are infrequent.15,25,26,27  The Systemic Immunosuppressive 
Therapy for Eye Disease (SITE) Cohort Study estimated the drug- free remission rate in 
intermediate uveitis at 8.6%/person- year (PY). 25  I n juvenile idiopathic arthritis (JIA) -associated 
chronic uveitis, the median time to a drug- free remission for mild disease is ~10 years, and only 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 15 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  ~25% of those with severe disease ever achieve a remission.26,27  The Mount Sinai Multifoc al 
Choroidopathy Study reported that no patients with these posterior uveitides were in drug-free 
remissions at 2 years of follow -up, and only 11% were able to discontinue prednisone 
successfully, despite the use of immunosuppression in all patients.16 The SITE Cohort Study 
estimated the rate of drug -free remissions for each non- alkylating agent immunosuppressive 
drug at 5 to 9%/PY.28,29,30,31  In the MUST Trial and Follow -up Study, only ~25% of participants 
treated with systemic therapy were in drug -free remissions at 7 years of follow -up.15  Hence 
long-term, chronic therapy with oral corticosteroids and/or immunosuppression typically is 
needed to control these diseases and preserve vision.  
   
Oral corticosteroids and immunosuppression have the potential for systemic side effects, but 
most are reversible with dose reduction or discontinuation of the appropriate agent.13,14  In the 
MUST Trial and Follow -up Study, there was no significant increase in systemic adverse effects 
through 7 years of follow -up among those assigned to systemic therapy versus those assigned 
to trea tment with a regional, intraocular therapy  (the fluocinolone acetonide implant ) with the 
one exception.  T hose assigned to systemic therapy were more likely to be given antibiotics for 
infections.15,21,22,24  A key to the successful management of this systemic approach is tapering 
prednisone to relatively safe doses.  Meta- analyses of trials in rheumatoid arthritis have shown 
that prednisone at a dose of < 7.5 mg/day appears safe for the intermediate- term (~ 2 years),32 
and in the MUST Trial and Follow -up Study (in which minimal systemic side effects occurred), 
the median dose of prednisone among those still on prednisone at 7 years of follow -up was 6.25 
mg/day.15  However, long- term studies of patients with rheumatoid arthritis demonstrate that the 
risks of overall and cardiovascular mortality both increase with the cumulative dose of 
prednisone,33 suggesting that efforts must be made to discontinue or at least minimize the daily 
dose of oral corticosteroids.  Although doses of prednisone of 5 to 7.5 mg/day might be tolerated for years, they cannot be used indefinitely, due to the increased risk of cardiovascular 
disease.
33  Improved corticosteroid- sparing immunosuppression am ong uveitis patients is critical 
to minimizing the use of systemic corticosteroids and improving patients’ long- term outcomes  
given that long -term, potentially life- long, treatment may be required and the relatively low rate 
of remission .14  
  Immunosuppressive drugs include small molecules (conventional agents) and biologic agents.  
The principal small molecule immunosuppressive drugs include the antimetabolites, azathi oprine, methotrexate, and mycophenolate; the calcineurin inhibitors, cyclosporine and 
tacrolimus; and the alkylating agents, cyclophosphamide and chlorambucil.
14,28,29,30,31,34,35,36  The 
biologic agents most often used for treatment of the uveitides are anti -tumor necrosis factor 
(TNF) -α monoclonal antibodies (e.g. , infliximab, adalimumab), although there are case reports 
and small case series with other agents.37,38,39,40,41,42  In the MUST Trial and Follow -up Study, 
88% of participants assigned to systemic therapy received immunosuppression; all of these patients received conventional immunosuppression as the initial agent. Currently, the majority of 
patients with uveitis receiving immunosuppression are treated with antimetabolites or calcineurin inhibitors.  Alkylating agents may be more effective,
34 but their use has been 
curtailed due to their increased cancer risk.43,44,45,46,47 Biologic  agents also have been used less 
often in the past, in part due to restricted access in the US prior to US FDA approval for uveitis.  Data from the SITE Cohort Study suggest that antimetabolites and calcineurin inhibitors, when 
used as the only immunosuppression agent, are effective in controlling the inflammation and 
allowing tapering of prednisone to <10 mg/day in ~40- 55% of patients by 6 months of 
treatment.28,29,30,31  As such, dose escalation of immunosuppressive agents, switching agents, 
and combination therapies (e.g. , an antimetabolite with a calcineurin inhibitor) commonly are 
needed.14,16  When uveitis reactivation occurs, the dose of prednisone is increased unti l the 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 16 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  uveitis is inactive again and the prednisone taper resumed, sometimes more slowly, increasing 
the cumulative exposure to oral corticosteroids and the potential for side effects.  
   
In June 2016, adalimumab (Humira®, AbbVie, Chicago, IL), a fully human monoclonal antibody 
to TNF -α, administered subcutaneously, was approved by both the US FDA and by the 
European Commission for the treatment of noninfectious, intermediate, posterior, and panuveitides.  These approvals were based on two industry -sponsored, randomized, placebo-
controlled, double masked, drug -licensing trials  comparing  adalimumab versus placebo for 
patients with active and inactive uveitis (VISUAL I and II, respectively).  These trials 
demonstrated the superiority of adalimumab over placebo by prolonging the time to treatment failure (uveitis relapse) among participants on a rapid corticosteroid taper to discontinuation.
37,38  
In the VISUAL III treatment extension study participants were permitted to use low -dose oral 
corticosteroids.  In VISUAL III, ~75% of patients had inactive uveitis with a prednisone dose <5mg/day, beginning at 11 weeks after entry and continued through at least 1 year of follow -up.  
Furthermore, in VISUAL III, the mean dose of prednisone over time was 2 mg/day. (Douglas, Kevin, AbbVie, personal communication, 2017).  These data suggest that adalimumab may be 
superior to conventional immunosuppression as corticosteroid- sparing therapy (success rates of 
~40 to 55% in the SITE Cohort Study
28,29,30,31 and long- term mean doses of prednisone of 5 -6 
mg/day in the both Mount Sinai Multifocal Choroidopathy Study and the MUST Trial Follow -up 
Study15,16).  A recently -published, randomized, placebo- controlled clinical trial of  adalimumab 
added to methotrexate demonstrated its efficacy in managing JIA -associated uveitis in children.   
Furthermore, aside from an increased risk of infection (also seen with conventional immunosuppression in the MUST Trial and Follow- up Study) and injection site reactions, 
adalimumab appears relatively safe for long- term use.
48,49,50 Although the initial SITE Cohort 
Study publication suggested a possible increased risk of malignancy with anti -TNF biologic 
agents,45 these data were from a very small sample size, and sensitivity analyses of the 
estimates were unstable.  Large observational databases48,49 and meta -analyses50 have 
demonstrated no increased risk of malignancies with anti -TNF treatment, except possibly non-
melanoma skin cancer, a risk also sometimes reported with conventional, small molecule 
immunosuppression.46 The potential superiority as a corticosteroid -sparing agent and apparently 
similar safety of adalimumab to conventional immunosuppressive agents suggest the need for a randomized, comparative effectiveness trial comparing adalimumab to conventional 
immu nosuppression for the treatment of non- infectious, intermediate, posterior, and 
panuveitides.   
 A key feature in the management of the uveitides is successful control of the 
inflammation.
51,52,53  When evaluated using time- updated methodology, the presence of any 
inflammation increases the risks of visual impairment and blindness by 2- and 3- fold, 
respectively, and there appears to be a dose- response effect with greater inflammation resulting 
in higher risks of visual impairment and blindness.51,52,53  Therefore, the definition of treatment 
success for corticosteroid -sparing includes tapering prednisone to < 7.5 gm/day while 
maintaining inactive disease.9,16,32 Measurement  of uveitis control varies by specific disease.  
For example, fo r intermediate uveitis, vitreous haze is a good measure of activity (and has been 
used for US FDA drug approval of Ozurdex®),9,54 but for serpigi nous choroiditis it is not, as there 
is no vitritis with serpiginous.  For serpiginous choroiditis, multimodal imaging has demonstrated 
that fundus autofluorescence (FAF) correlates well with disease activity, and it has become the 
standard method for foll owing such patients.55  Similarly, for birdshot chorioretinitis (BSCR), 
vitreous haze typically is mild, and FAF is not helpful, but prevention of loss of peripheral visual field (and sometimes reversal of loss) from active disease is an important measure.
17,18,55  To 
address this heterogeneity, the ADVISE Trial will use disease-specific assessments for 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction │ 17 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  determining active vs. inactive disease in each participant (see Table 2.  Visit and Examination 
Schedule in section 3.7 below  and the Guidelines for Determining Inactive Disease in the 
ADVISE Manual of Procedures ). 
 
1.8 Preliminary studies  
The MUST Trial and Follow -up Study compared the fluocinolone acetonide intraocular implant 
(a strictly regional corticosteroid approach, designed to last 3 years, with re -implantation as 
needed) to systemic therapy with oral corticosteroids and immunosuppression for the treatment 
of non -infectious, intermediate, posterior, and panuveitides.15,21,22,23,24 The MUST Trial enrolled 
255 participants (Table 1), and the primary outcome was change in visual acuity from baseline.  
At 2 and 4.5 years of follow -up, the implant and systemic therapy had similar visual acuity 
outcomes; both treatments controlled the inflammation in the large majority of participants; the implant had better control of the inflammation but at a cost of higher rates of ocular hypertension (OHT), glauc oma, and cataracts; and both groups had similar rates of systemic side effects, 
except for a greater use of antibiotics for infections in the systemic group.
21,22,23,24  However, at 7 
years of follow -up visual acuity outcomes significantly favored systemic therapy, with greater 
rates of ocular adverse events in the implant group, but generally similar rates of systemic 
adverse events in both groups.15 Furthermore, throughout the 7 years of follow -up, participants 
on systemic therapy maintained good visual acuity (mean ~20/40).   
 
Clinician -reported causes of visual impairment suggested that patients in the implant group 
more often had retinal lesions/scars as the cause.  These data suggest that systemic therapy has advantages over strictly regional therapies for the long -term management of these more 
severe, vision- threatening uveitides.  In the systemic group, 88% of participants received 
immunosuppress ion in addition to oral corticosteroids .  Of the 88% of participants using 
immunosuppression, 85% (75% of the entire cohort) initiated immunosuppression with a single 
immunosuppressive agent, and 15% (13% of the entire cohort) with a combination of immuno -
suppressive agents.  The most commonly used single- agent immunosuppressive drugs were 
mycophenolate 41%, methotrexate 29%, azathioprine 7%, and cyclosporine 6%.  The most 
commonly used combination regimens were mycophenolate and cyclosporine 5%, azathiopri ne 
and cyclosporine 3%, and methotrexate and cyclosporine 2%.  For each participant the choice 
of immunosuppressive drug was made by the investigator at the clinical center, based on the 
patient’s needs and the drug’s side effect profiles (e.g., methotrexate is avoided in patients with 
liver disease), but the drugs were used in a standardized fashion following MUST Trial  
guidelines.
14,21  Adherence to protocol for the use of immunosuppressive drugs was monitored 
regularly by a Medical Therapy Quality Assurance Committee (MTQAC), thereby assuring their proper and consistent use.  
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Introduction│  18 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
 
 
Table 2.  Distribution of uveitic diseases in the MUST Trial  
Disease                 % Participants  
Intermediate uveitis (including pars planitis)  27 
Undifferentiated anterior and intermediate uveitis  19 
Undifferentiated or sarcoid -related panuveitis  17 
Multifocal choroiditis with panuveitis  10 
Birdshot chorioretinitis  9 
Vogt-Koyanagi -Harada disease  6 
Undifferentiated retinal vasculitis  5 
Behçet disease  3 
Multiple sclerosis associated uveitis  1 
Other*  3 
*Sympathetic ophthalmia, serpiginous choroiditis, and punctate inner choroiditis each 1%  
 
 1.9 Rationale for trial  
Available data suggest that each of the conventional, non- alkylating- agent, immuno- suppressive 
drugs is effective in successful corticosteroid- sparing with inflammation control in ~40- 55% of 
patients  when used  as a single immunosuppressive agent in conjunction with 
corticosteroids.
28,29,30,31,34 hence, combination therapy often is needed.16  In June 2016, the 
United States (US) Food and Drug Administration (FDA) approved adalimumab, a fully -human 
monoclonal antibody to TNF- α, for the treatment of non -infectious intermediate, posterior, and 
panuveitides.37,38  Monoclonal antibody therapies, particularly those against TNF- α, have 
transformed the mana gement of rheumatic diseases, such as rheumatoid arthritis and 
ankylosing spondylitis, and largely have supplanted older Disease Modifying Anti -Rheumatic 
Drugs (DMARDs).  Although the relative effectiveness of adalimumab vs.  conventional 
immunosuppression for the treatment of non- infectious intermediate, posterior, and panuveitides 
is unknown, data from the VISUAL III study suggest that adalimumab may be superior to 
conventional immunosuppression for corticosteroid sparing while maintaining uveitis control.   In 
VISUAL III uveitis control was maintained in ~75% of participants with prednisone doses <5 
mg/day (Tari S, AbbVie, personal communication, 2016).  Minimizing the daily dose of 
prednisone is important, as there is a cumulative effect of oral corticosteroids on the risk of 
cardiovascular disease and mortality.33 Therefore, the ADVISE Research Group proposes to 
perform a randomized, comparative effectiveness trial of adalimumab vs. immunosuppression 
with conventional agents for the treatment of non- infectious intermediate, posterior, and 
panuveitides, the ADlamimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial.   
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Objective and study hypothesis  │ 19 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  2. Objective and study hypothesis  
 
2.1 Objective and specific aims  
The ADVISE Trial is a randomized, parallel- treatment, comparative effectiveness trial, 
comparing adalimumab to conventional (small molecule) immunosuppression for the treatment 
of non -infectious, intermediate, posterior, and panuveitides.    
 The specific aims of the ADVISE Trial are to:  
 1. Compare the relative effectiveness of adalimumab vs. conventional 
immunosuppression at controlling ocular inflammation while permitting tapering of 
prednisone to < 7.5 mg/day .  
  
 2. Compare the relative effectiveness of adalimumab vs. conventional immunosuppression at controlling ocular inflammation while permitting tapering and discontinuation of prednisone.  
 
 3. Compare the visual acuity outcomes, rates of ocular complications of uveit is (e.g. , 
macular edema), and drug- related adverse event profiles between the two treatment 
groups.  
  
 4. Compare the quality of life profiles between the two treatment approaches.   
 
2.2 Hypotheses  
Based on the preliminary data we hypothesize that adalimumab will be superior to conventional 
immunosuppression for successful corticosteroid- sparing with no clinically important increase in 
systemic adverse events.   
 
Primary Hypothesis  
Adalimumab will be superior to conventional immunosuppression for corticosteroid sparing, as 
determined by the  proportion achieving the primary outcome, namely inactive uveitis and 
prednisone <7.5 mg/day for 2 visits > 28 days apart by 6 months of follow -up.  
 
Secondary hypotheses are:  
 1. Adalimumab will be superior to conventional immunosuppression for corticosteroid-sparing by one year of follow -up as determined by the proportion achieving  inactive 
uveitis at prednisone ≤ 7.5 mg/day for 2 visits > 28 days apart within one year of 
follow -up; 
 
 2.  Adalimumab will be superior to conventional immunosuppression for maintaining 
control of inflammation after discontinuation of prednisone for 2 visits >28 days apart 
by one year of follow -up. 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 20 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  3. Design 
 
The ADVISE Trial is a randomized, parallel- treatment, comparative effectiveness trial, 
comparing adalimumab to conventional (small molecule) immunosuppression for  corticosteroid 
sparing in the treatment of non -infectious, intermediate, posterior, and panuveitides.  
 
3.1 Design elements  
• Randomiz ed, parallel -treatment, controlled comparative effectiveness clinical trial  
• Randomization stratified by:  
- Whether patient is receiving zero or one immunosuppressive agent  at enrollment  
- Whether the initial dose of prednisone in the trial will be <30 mg/day or ≥ 30 
mg/day  
• The unit of randomization is the patient  
• The unit of analysis for the primary outcome is the patient  
• Allocation ratio 1:1  
• Multicenter , international 
• Fixed sample size = 222 (111 per treatment group)  
• Unmasked treatment administration and outcome assessments (participants, study 
ophthalmologists, visual function examiners, and study coordinators are all unmasked).   
• Masked assessment of  photographic images and OCT by the RC (graders masked)  
- All patients  
 OCT at baseline, 3, 6, and 12 months  
 Retinal color photographs at baseline, 6 and 12 months   
• Disease -specific image or OCT, as applicable, at baseline, 1, 3, 6, and 12 
months Anniversary close- out at the 12- month visit  
• First patient enrolled in September 2019; the end of the trial (completion of follow -up of 
last patient enrolled) is expected to be February 2023.  
• Conducted under IND 132532  
 
 
3.2 Randomized t reatment  arms  
• Adalimumab 
- 80 mg subcutaneously once as the initial dose  
- 40 mg subcutaneously  a week later,  then 40 mg subcutaneously  every other 
week  thereafter  
 
• Conventional immunosuppression  
The treatment of participants randomized to conventional immunosuppression will 
depend on whether or not patient is using an immunosuppressive agent at enrollment 
and, if one is being used, the type of i mmun osuppressive agent in use .  
- For patients receiving no immunosuppressive agents at the time of enrollment  
the initial immunosuppressive drug will be an antimetabolite (azathioprine, 
mycophenolate, or methotrexate) 
 
- For patients already on one immunosuppressive drug at enrollment, the original 
drug will be continued at the dose at baseline.   Additional treatment will be based 
on the drug already being received at baseline:   
 Those on an antimetabolite will receive a calcineurin inhibitor 
 Those on a calcineurin inhibitor will receive an antimetabolite  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 21 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
 
 
3.3 Trial schema tic 
 
 
  

ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 22 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  3.4 O utcomes  
3.4.1  Primary outcome 
The primary outcome of the ADVISE Trial will be a corticosteroid- sparing treatment success, 
defined as inactive uveitis, on prednisone < 7.5 mg/day for 2 consecutive visits >28 days apart 
within the first 6 months after randomization.9,16,28,29,30,31,34  The SITE Cohort Study required 2 
consecutive visits > 28 days apart to avoid overestimation of benefits among patients who 
transiently achieve corticosteroid- sparing, but promptly relapse at the next visit.28,29,30,31,34 We 
will use a similar meth odology for the same reasons.  The prednisone taper schedule used in 
the ADVISE Trial (see Table 4 in section 4.2.2) is designed to permit clear evaluation of this 
outcome.   
 
3.4.2  Secondary  outcomes  
  Secondary corticosteroid sparing outcomes  
 
 1. The ability to achieve inactive uveitis and prednisone < 7.5 mg/day for 2 consecutive 
visits >28 days apart within one year of randomization. 
 
 2. The ability to achieve inactive uveitis and completely discontinue prednisone for  2 
consecutive visits > 28 days apart within   6 months and one year of randomization. 
 
 3. Prednisone exposure (e.g. , cumulative prednisone dose and/or mean prednisone dose) 
in the 2 groups over 1 year with emphasis on the 6- month (primary outcome) and 1 -year 
(end of follow -up) visits . 
    
    Other secondary outcomes (assessed at every visit unless otherwise indicated)   
 
 4. Best corrected visual acuity measured after a standardized refraction using l ogarithmic 
visual acuity charts 21,56,57 over 1 year with emphasis on the 6 -month (primary outcome) 
and 1- year (end of follow -up) visits . 
 
 5. Incidence of the following infections  over 1 year with emphasis on the 6 -month (primary 
outcome) and 1- year (end of follow -up) visits : 
a. Infections requiring antimicrobial therapy  
b. Tuberculosis (clinical diagnosis of tuberculosis)  
c. Invasive fungal infections  
d. Dermatomal or disseminated herpes zoster  
 
Diagnosis of these entities will rely on medical record confirmation thereof, but specific testing will not be performed prospectively to ascertain the individual infections, which 
likely will be unusual.   
 
 6. Systemic adverse events, e.g., cytopenias, elevated creatinine, elevated liver enzymes 15
,21,22,23,24 over 1 year with emphasis on the 6 -month (primary outcome) 
and 1- year (end  of follow -up) visits . 
 
 7. Macular edema58,59,60,73 over 1 year with emphasis on the 6 -month (primary outcome) 
and 1- year (end of follow -up) visits . 
 
 8. Quality of life (QoL) data as assessed using the following patient reported outcomes that 
have been used in prior MUST 61,62,63,64,65,66,67  over 1 year with emphasis on the 6- month 
(primary outcome) and 1 - year (end of follow -up) visits  
a. Health Utility (EuroQoL 5 -dimension and visual analog scales)  
b. Generic Health- related Quality of life (SF -36) 
c. Vision -related QoL (the 25- item NEI Visual Function Questionnaire [VFQ])  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 23 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
3.4.3  Disease- specific assessment to permit ascertainment of outcomes 
pertaining to activity of uveitis  
As there is no one uveitis activity measure or simple combination of measures appropriate for all 
intermediate, posterior, and panuvei tides , disease -specific testing/assessment  will be used to 
determine whether the uveitis is active. The specific  uveitic diagnosis documented at enrollment  
(including undifferentiated uveitides by anatomic class)  will dictate the disease- specific tests 
required (Table 2)  and the criteria for determining inactive uveitis for that participant (Guidelines 
for Determining Inactive Uveitis in the ADVISE Manual of  Procedures) .  If the unlikely situation 
is encountered in which different eyes have different diagnoses, each eye will be assessed using the disease -specific tests indicated for each eye’s diagnosis  and both eyes must have 
inactive uveitis for the patient  to be counted as inactive for corticosteroid- sparing outcomes. 
These tests will be performed according to the schedule outlined in Table 2 .  Some of the 
assessments are part of the eye examination (e.g. , grading of anterior chamber cells and of 
vitreous haze), but other assessments involving ancillary testing will be done only for selected diseases (e.g. , FAF, visual fields, fluorescein angiography) for which the results are relevant to 
the determination of activity.  However, for each participant, the tes t(s) and methods of 
assessment will be the same from baseline throughout  the duration of the trial, so that a 
longitudinal assessment of active vs. inactive can be made consistently on an individual participant basis.  
 
Uveitides included in the ADVISE Trial which require specific testing in addition to clinical 
examination to determine activity/quiescence include:  
  
• Multifocal choroidal/retinal pigment epithelium inflammation including undifferentiated 
panuveitides  (except birdshot chorioretinitis ):  For most such cases, fundus 
autofluorescence shows hyper -autofluorescent spots or borders with active disease and 
hypo- autofluorescent spots with inactive scarring.55,68,69 Fundus autofluorescence is non -
invasive, easily performed, and will be done at each follow -up visit during the trial in 
patients for which it is indicated.  
 
• Birdshot chorioretinitis :  An exception to the utility of autofluorescence for multifocal 
choroidopathies is birdshot chorioretinitis, where fundus autofluorescence does not 
correlate with active disease.55 However, patients with active birdshot choroiditis suffer a 
progressive loss of visual field.  The earliest changes are a loss of peripheral field, not 
adequately captured on automated perimetry of the central field (e.g. , the Humphrey 30-
2), but well captured with quantitative Goldmann perimetry18 or alternative evaluations of 
the peripheral field (e.g., automated perimetry using both the SITA -fast 30-2 and the 
peripheral 60 [ P60], a suprathreshold screening test of the peripheral field).  Therefore, 
patients with birdshot will undergo one of these two forms of  visual field testing at each 
visit throughout the trial.  Quantitative Goldmann visual fields (QGVFs) are performed in 
a standard fashion and produce visual field scores for I/4 and IV/4 isopters (normal values >560˚ of total field and >700˚ of total field, respectively).  The inter -test v ariation 
in the field is estimated at 16%, so scores within 16% of the previous field will be 
considered stable.18 Published data have demonstrated improving QGVF scores with 
immunosuppression, vs. declining ones without treatment.16,18  Goldmann perimetry is 
not universally available; therefore  clinical centers without it will use automated perimetry 
with both evaluation of the central and peripheral field (e.g. , Humphrey 30-2 SITA -fast 
and P60 screening test) , in order to address the limitations of Humphrey 30- 2 testing 
alone.  As with QGVFs, automated perimetry results within the variability of the test will 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 24 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  be considered “stable” (e.g. , <3 dB mean deviation for the 30 -2 and a change of < 8 
spots missed for the P60, a supra -threshold screening test [Ramulu P, unpublished data, 
personal communication, 2017] ). 
 
• Early stage Vogt -Koyanagi -Harada disease :  OCT will be used to determine the 
resolution of exudative retinal detachment s. 
 
• Late stage Vogt -Koyanagi -Harada disease:  Fundus autofluorescence will be used to 
evaluate chorioretinal lesions  
 
• Retinal vasculitis and panuveitis with retinal vasculitis (including undifferentiated 
panuv eitis with retinal vasculitis and panuveitis with retinal vasculitis with systemic 
disease) :  Fluorescein angiography will be used to evaluate patients with these 
conditions .  Because resolution of intraretinal hemorrhages can take 3 months after 
vascular occlusion, the absence of new areas of intraretinal hemorrhage or retinal 
infarction  or non- perfusion  in conjunction with no new or increase in areas of retinal 
vascular staining and leakage  will be used as evidence of uveitis control on fluorescein 
angiog raphy.    
 
Structural complications, such as macular edema, epiretinal membrane formation, and choroidal 
neovascularization, will be scored separately, as they do not necessarily indicate active 
inflammation.   
 
In order to obtain consistency of evaluation, the RC will conduct a training session for the study  
ophthalmologist s, emphasizing interpretation of the various modes of imaging and the 
determination of active vs. inactive disease.  In addition, the RC will provide a guidebook with 
examples of active and inactive disease based on the disease- specific imaging by disease.  
Real-time central determination of activity by the RC is not feasible logistically, as treatment 
decisions must be made at the time of the participant’s visit, and determination of activity requires examination of the patient as well as the images.  However, images taken at the 
baseline, 1-, 3-, 6-, and 12 -month visits, including disease- specific images, will be sent to the 
RC for interpretati on and will be used in quality control evaluations . 
 
The MTQAC will monitor activity assessment with support from the CC  from regular screen as 
well as ad hoc assessments (e.g. , site visits) .  At month , the CC will screen the data stream for 
discrepancies between the site determination of activity and the corresponding disease -specific 
criteria for each eye with uveitis.  In addition, the CC will compare the RC and clinical evaluation 
of disease -specific images collected at baseline, 1- , 3-, 6-, and 12 -mont h visits.  Discrepancies 
will be flagged and forwarded to the MTQAC, which will recommend corrective action as 
needed.      
 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 25 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
3.5 Eligibility criteria  
Inclusion criteria  
 
 1. Age 13 years  or older  
 
 2. Weight 30 k g (66 lbs ) or greater  
 
 3. Active or recently active ( ≤ 60 days) non- infectious  intermediate, posterior, or panuveitis  
 
 4. Prednisone indication meets one  of the following:   
a. Active uveitis requir ing one of the following  
i. Initiation of prednisone at dose  greater than 7.5 mg/day  
ii. Increasing prednisone dose to greater than 7.5 mg/day  
iii. Currently receiving dose greater than 7.5 mg/day  
b. Inactive uveitis on current dose greater 7.5 mg/day  
 
 5. Initiation or addition of an immunosuppressive drug (i.e., a conventional 
immunosuppressive drug or adalimumab) is indicated  
 
 6. If currently receiving a conventional immunosuppressive drug, the drug and dose have 
been stable for at least 30 days  
 
 7. Patient able and willing to self -administer subcutaneous injections or have a qualified 
person available to administer subcutaneous injections  
 
 8. If post erior segment disease is present, ability to assess activity  in at least one eye with 
uveitis  
 
 9. Visual acuity of light perception or better  in at least one eye with uveitis  
Exclusion criteria  
 
 1. Active tuberculosis or  untreated latent tuberculosis (e.g., positive interferon- γ release 
assay [IGRA] test, such as Quantiferon- gold)  
 
 2. Untreated active hepatitis B or C  infection  
 Active hepatitis B is defined as positive surface antigen; active hepatitis C is 
defined as positive antibody and positive poly merase chain reaction (PCR)    
 
 
 3. Any of the following baseline lab values  
a. White blood count <3500 cells per microliter  
b. Platelets <100,000 per microliter  
c. Hematocrit <30%  
d. AST or ALT >1.5X upper limit normal value 
e. Serum creatinine >1.1X upper limit normal value 
 
 4. Behçet disease  
 
 5. Multiple sclerosis  or other demyelinating disease  
 
 6. For patients with anterior/intermediate  or intermediate uveitis  without systemic disease , 
abnormal magnetic resonance imaging (MRI) of the brain consistent with demyelinating 
disease  
 
 7. Severe uncontrolled infection 
 
 8. Receipt of a live vaccine within past 30 days  
 
ADVISE PROTOCOL 1.3 (1 2 OCT 2020)  Design  │ 26 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   9. Moderate to severe heart failure (NYHA class III/IV)  
 
 10. Active malignancy  
 
 11. Use of anti -TNF monoclonal antibody therapy within past 60 day s 
 
 12. History of adalimumab intolerance or ineffectiveness  
 
 13. Hypersensitivity to any of the study treatments or their excipients  
 
 14. Current treatment with an alkylating agent  
 
 15. Current treatment with more than one immunosuppressive drug, not including oral 
corticosteroids  
 
 16. Shorter -acting regional corticosteroids administered within the past 30 days in any 
eye(s) with uveitis   
 
 17. Long- acting ocular corticosteroid implants, i.e., fluocinolone acetonide implant  (e.g., 
Retisert®, YutiqTM, Iluvien®) placed within past 3 years unless uveitis is active in all eye(s) 
with an implant   
 
 18. Systemic disease that is sufficiently active such that it dictates therapy with systemic 
corticosteroids or immunosuppressive agents at the time of enrollment  
 
 19. Immunodeficiency disease for which immunosuppressive therapy would be 
contraindicated according to best medical judgment  
 
 20. Pregnancy  or lactation  
 
 21. For persons of child -bearing potential  or impregnating potential, unwillingness to use 
appropriate birth control  (abstinence, combination barrier and spermicide, hormonal , or 
intrauterine device) for the next 18 months or plans to become a biological parent within 
the next 18  months.  
 
* In the UK, use of combination barrier and spermicide alone does not meet birth control 
requirements.  
 
† UK female study participants must use highly effective methods of contraception.  
UK male study participants must use condoms for at least 6 months after the end of 
study treatment and their female partners of child- bearing potential are recommended 
to use highly effective contraception for the same duration. In addition, m ale 
participants should not donate semen during therapy or for 6 months following 
discontinuation of study treatment. 
 
 22. Medical problems or drug or alcohol dependence problems sufficient to prevent 
adherence to treatment and study procedures.  
  
3.6 Stratification and r andomization  
After informed consent is obtained, eligible participants will be stratified based on: 1) whether 
they are receiving no or one immunosuppressive agent s and (2)  whether their  initial dose of 
prednisone in the trial will be <30 mg/day or > 30 mg/day .  Participants will be randomized 1:1 to 
adalimumab or conventional immunosuppression by variable- length permuted blocks within 
these 4 strata.  The randomization schedule will be produced in advance by the CC, and the 
randomization revealed via the ADVISE  website after eligibility and stratum are confirmed.  
 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Design  │ 27 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  3.7 Data collection schedule  
Participants will be followed monthly for 6 months, and every two months thereafter until 
anniversary study closeout 1 year after randomization.  The visit and examination schedule is 
given in  Table 2. 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Table 3.  Visit and examination schedule  │ 28 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
 Table 3.  Visit and examination schedule  
Month  BL* 1 2 3 4 5 6 8 10 12 
Visit ID  V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 
 
All patients            
Visual acuity† X X X X X X X X X X 
Medical, ophthalmic, and treatment history  X X X X X X X X X X 
Weight and blood pressure  X X X X X X X X X X 
Height  X          
Eye examination  X X X X X X X X X X 
Optical coherence tomography  (OCT)+ X   X   X   X 
Retinal color photo graph s‡ X      X   X 
Complete blood count & chemistry panel§ X X X X X X X X X X 
Quality of life (Euro QoL, SF -36, NEI -VFQ)  X   X   X   X 
           
Disease -specific test s           
  Disease                                         Test(s)           
   Birdshot chorioretinitis              Visual field¶ X X X X X X X X X X 
   Choroiditis  (all except birdshot)        FAF║ X X X X X X X X X X 
    VKH, early disease                      OCTɅ X X X X X X X X X X 
    VKH, late disease                        FAF X X X X X X X X X X 
    Retinal vasculitis  and                   FA#     
      panuveitis with retinal vasculitis  
 X X X X X X X X X X 
Tests to identify exclusion characteristics 
prior to enrollment            
Interferon -γ release assay for tuberculosis  
(all patients) ** X          
Hepatitis B panel%;hepatitis C antibody  (all) X          
Gadolinium enhanced MRI for patients with 
anterior/intermediate or intermediate uveitis  
without  systemic dise ase only†† X          
Pregnancy test for women of child bearing 
potential  X 
          
 
 * BL = baseline 
 † Evaluation of best corrected visual acuity after standard refraction  
 + OCT centered on fovea  
  ‡ 9-field 50 or 60˚ photographs or wide-field photograph (e.g. , Optos)  
  § Including creatinine, liver enzymes  and serum  glucose  
   ¶ Either quantitative Goldmann perimetry  or automated perimetry with Humphrey SITA -fast 30-2 and S creening  P60    
may be used, but once chosen, the visual field testing should be the same for all visit for each individual patient  
 ║ FAF= fundus autofluorescence  
 Ʌ OCT  centered on fovea & additionally , as needed,  OCT centered to capture area with greatest subretinal thickness  
  Δ VKH = Vogt -Koyangi -Harada  
 # FA = f luorescein angiography  
** E.g., Quantiferon Gol d   
% Including hepatitis B surfac e antigen, hepatitis B core antibody, and hepatitis B surface antibody  
††  Gadolinium enhanced MRI = magnetic res onance imaging of the brain with a gadolinium based contrast agent  
    (GBCA)  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment  │ 29 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  4. Treatment  
4.1 Overview  
All patients enrolled in the study will be treated with prednisone, along with randomization to one 
of the two corticosteroid- sparing treatment strategies being studied.  Approaches for 
administration of ancillary treatments that might be required are specified by the protocol.  
 The decision to taper, escalate, or change therapy will be dictated by the protocol and the study 
ophthalmologist’s evaluation of activity.  The study ophthalmologist will manage the medications 
according to the treatment guidelines  described in the protocol  and further  detailed in the 
ADVISE Manual of Procedures, accounting for any side effects encountered.  The unit of analysis will be the patient, so that active disease in either eye will cause the patient to be classified as having active disease and managed accordingly.  In the unlikely event that a 
patient has different diagnoses in the two eyes, each eye will be assessed as indicated in the 
ADVISE disease -specific guidelines for determining inactive disease (Manual of Procedures, 
section 4.2) for the eye’s diagnosis, and both eyes must have inactive uveitis for the patient to 
be counted as inactive for the corticosteroid- sparing outcomes.  The presence of complications 
of the uveitis (e.g. , macular edema, epiretinal membranes) will be scored separately  and will not 
be used to determine uveitis activity, following consensus recommendations .
.9  
  
This section provides study treatment guidelines which cover many but not all situations.  The guidelines are based on the following basic principles.  
1) Initial therapy involves initiating study -spec ified immunosuppression with initiation of or 
an increase in prednisone dose if uveitis is active  
2) Initiate prednisone taper once activity has been quieted or maximum duration of high-
dose prednisone has been reached  
3) If uveitis is not controlled after maximum duration of high dose prednisone and maximum 
advancement of im munosuppression per guidelines, treatment is per best medical 
judgment.  
4) Reactivation during follow -up is treated by   
a.  Increasing the dose of prednisone  
b. Advancing immunosuppression if indicated  
 
For situations that are either not covered by these guidelines or are nuanced so that guidelines 
may not be followed exactly, study ophthalmolog ists should follow best medical judgement .   
Additionally , study ophthalmologists may consult members of the Medical Quality Assurance 
Committee  (MTQAC) for guidanc e. 
 
The time points (e.g., 4 weeks) in the treatment guidelines are targets; variations due to 
scheduling of study visits are both permitted and expected .  
  4.2 Systemic corticosteroids 
All participants will be treated with prednisone  (or an equipotent dose of an alternative 
corticosteroid if prednisone is clinically inappropriate or unavailable). The maximum allowed 
prednisone dose is 1 mg/kg/day up to a maximum of 60 mg/day  (i.e., 1 mg/kg/day for  patients  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment  │ 30 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  under 60kg and 60 mg/day for patients  at or above 60 kg).  Table 3 summarizes the initial 
prednisone dosing for the scenarios described below.  
4.2.1  Initial prednisone dose  
• Patients  with active uveitis  not on prednisone:  
The initial dose of prednisone is the maximum allowed dose (i.e. , 1 mg/kg/day up to a 
maximum  of 60 mg/day ) for 2 weeks . Prednisone tapering will be initiated at 2 weeks per 
section 4.2.2 if the uveitis is controlled.  If the study ophthalmologist expects the uveitis 
to be controlled within 2 weeks, the prednisone tapering may be initiated automatically at 
2 weeks without a clinic visit.  Should uveitis fail to be controlled after 2 weeks  or if the 
study ophthalmologist did not expect it to be controlled within 2 weeks , the maximum 
allowed dose will be continued for 2 additional weeks (total of 4 weeks).  To avoid 
complications of systemic corticosteroid therapy, after 4 weeks of prednisone at the 
maximum allowed dose, prednisone tapering will be initiated per section 4.2.2.  If the 
uveitis is neither controlled nor substantially  improved such that it is expected to be 
inactive by next visit  (V03 in 4 weeks) , then, immunosuppression will be advanced per 
section 4.4.  Additional advancement of the immunosuppressive treatment will be 
implemented  according to guidelines  in section 4.4 until inflammation is controlled or 
else the best medical judgment point  of guidelines is reached.  
 
• Patients  already on prednisone with a reactivation of uveitis :  
The initial dose of prednisone will be increased according to the current dose and the 
severity of the reactivation. For patients on more than half of the maximum allowed dose 
(i.e., maximum dose is 1 mg/kg/day up a maximum of 60 mg/day), the dose will be 
increased to the maximum  allowed dose.   For patients  on less than half of the maximum 
allowed dose, the dose will be at least doubled but may be increased to any dose 
between double the current dose and the maximum allowed dose depending upon the 
severity of the disease.   Should uveitis fail to be controlled after 2 weeks  of this 
increased prednisone dose , then an additional 2 weeks of prednisone  at the maximum 
dose, regardless of the initial dose, will be given . If the study ophthalmologist did not 
expect the uveitis to be controlled within 2 weeks, then the initial prednisone period may be 4 weeks. To avoid complications of systemic corticosteroid therapy, prednisone 
tapering will be initiated at week 4 per section 4.2.2 .  At V02 if the uveitis is neither 
controlled nor substantially improved such that it is expected to be inactive at  the next 
visit (V03 in 4 weeks), then, immunosuppression will be advanced per section 4.4 .  
Additional advancement of the immunosuppressive treatment will be implemented according to the guidelines  in section 4.4.  until inflammation is controlled  or else the best 
medical judgment point on the immunosuppression guidelines  is reached.  
  
• Patients  with recently active but inactive uveitis by enrollment on prednisone >7.5 
mg/day :   
The dose will be held at that level (i.e., the >7.5 mg/day dose patient was on at 
enrollment) for 4 weeks after initiating the new immunosuppressive agent to enable that 
agent  to have an effect.  Prednisone tapering will be initiated at week 4. Should the 
patient’s uveitis become active within those four weeks, they will be managed as described in the preceding bullet. 
   
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  31 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
 
 
Table 4.  Initial prednisone dosing summary  
Status at 
enrollment  Initial dose  
(Week 0)  First  opportunity to 
taper *† 
(Week 2)  Second opportunity to taper  
(Week 4)  
Active, not on 
prednisone  Maximum allowed dose  
(1 mg/kg/day if < 60 kg  
 OR 60 mg/day if ≥  60 kg)  Controlled: Taper  
 
Not controlled: Hold at current dose  Controlled: Taper  
 Substantially improved
‡: Taper , 
but not below 7.5 mg/day  until 
inactive. Only advance 
immuno. suppression if control is 
not achieved after 4 more weeks.  
 
Not controlled: Taper but not below 7.5 mg/day and advance 
immunosuppression  
Reactivated, 
on prednisone  Current dose ≥ ½ maximum 
allowed dose §: Increase to 
maximum allowed dose  
  Current dose < ½ maximum allowed dose:  Increase to between double current dose and maximum allowed dose depending on severity  Controlled: Taper  
 
Not controlled at maximum  
dose: Hold at maximum  dose  
for 2 more weeks  
 
Not controlled while below maximum dose:  Increase to 
maximum dose for 2 weeks  Controlled: Taper  
 Substantially improved
‡: Taper. but 
not below 7.5 mg/day  until 
inactive . Only advance 
immunosuppression if control is 
not achieved after 4 more weeks.  
 
Not controlled: Taper ,but not 
below 7.5 mg/day  until inactive 
and advance immunosuppression  
Inactive, on 
prednisone  
 > 7.5 mg/day  Hold at dose at enrollment  Controlled: Continue on same 
dose  
 
Not controlled (i.e. 
reactivates): Follow 
instructions for ‘Reactivated, 
on prednisone’  Controlled: Taper  
 Not controlled (i.e. reactivates): Follow instructions for 
‘Reactivated, on prednisone’  
* If the study ophthalmologist does not expect the uveitis to be controlled at 2 weeks, then an initial course of 4 weeks 
of prednisone can be prescribed.  The first assessment of activity would occur at the next scheduled visit (i.e. in 4 
weeks).    
 If the study ophthalmologist expects the uveitis to be controlled at 2 weeks, then the corticosteroid taper can be 
automatically initiated at 2 weeks without a clinic visit.  The first assessment of activity would occur at the next 
scheduled visit (i.e. in 4 weeks)  
‡ Substantially improved such that uveitis is expected to be controlled by the next visit  
§ The maximum allowed dose is 1 mg/kg/day for participants < 60 kg and 60 mg/day for participants ≥  60 kg 
 
 
 
4.2.2  Prednisone tapering schedule and goals  
After initially obtaining (or maintaining) quiescence of uveitis with treatment(s) or when the 
prednisone dose has been used for the maximum duration described in section 4.2.1, 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  32 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  prednisone will be tapered as described in Table 4 below , starting from the dose of 
corticosteroids they begin tapering from . 
• The primary outcome of the trial  is a prednisone dose of ≤ 7.5 mg/day for 2 visits ≥ 28 
days apart with inactive uveitis . If a patient is begun on prednisone 60 mg/day, the 
primary outcome should be reached by 15 weeks of follow -up.   
• If a patient achieves the primary outcome, an attempt should be made to taper further 
and discontinue prednisone.  A range of tapering decrements for prednisone doses 
below 7.5 mg/day is necessary due to the need to taper prednisone more slowly among 
those already on long- term oral corticosteroid therapy to minimize corticosteroid-
withdrawal symptoms but still permit  discontinuation by 1 year of follow -up. 
• The prednisone dose should not be tapered below 7.5 mg/day if the patient has active 
uveitis unless required according to best medical judgement.  
• If uveitis reactivates during tapering, follow  the guidelines for prednisone dosing in the 
reactivation management guidelines in section 4.5.  
  
 
 
 
  Table 5.  Prednisone tapering schedule  
Dose  
(mg/day)  Decrement  
(mg/day)  Interval  
(decrease every)  
60 to 30 10 1 week  
30 to 15  5 1 week  
15 to 7.5  2.5 1 week  
7.5† Hold at 7.5  mg/day  until two study visits ≥  
4 weeks  (28 days ) apart have occurred*  
           <7.5† 1-2.5 2 weeks  
*Note: This may involve maintaining the dose for more than two consecutive 
study visits if they occur <28 days apart.  
† Do not taper below 7.5 mg /day until uveitis is inactive  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  33 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  4.3 C orticosteroid- sparing drugs 
Corticosteroid -sparing therapy will be implemented according to strategies assigned by 
randomization. P atients initially on one immunosuppressive drug will continue it in addition to 
the randomized treatment .  Because of the differences in treatment administration and the use 
of conventional agents with different treatment administration schedules, treatment 
administration will not be masked.  
 
4.3.1  Adalimumab treatment group 
Adalimumab dosing regimen  
• 80 mg subcutaneously once as  an initial dose  administered as soon as possible after 
randomization 
• 40 mg subcutaneously one week after initial dose and then 40 mg every two weeks  until 
the end of follow -up unless some contraindication to continuation arises  
 
The adalimumab dosing protocol in ADVISE is the FDA approved regimen for treatment of 
uveitis in adults , i.e., an initial dose of 80 mg followed by 40 mg given every other week starting 
one week after the initial dose.   The FDA approv ed regimen  for treatment of uveitis in pediatric 
patients (2 years of age or older)  ≥30 kg is 40 mg every other week  but does not include an 
initial dose of 80 mg .  In ADVISE adolescent patients (13 to <18 year olds) will receive an initial 
dose of 80 mg.  While an initial dose of 80 mg is not FDA approved for treatment of  uveitis in 
adolescents, an initial dose of 80 mg for  adolescent/pediatric patients is FDA approved for other 
conditions, e.g., for adolescent patients  ≥30 kg for treatment o f hidradenitis suppurativa and for 
pediatric patients ≥  40 kg for the treatment of  pediatric Crohn’s disease.  
 
Management of conventional immunosuppressive agents for patients who are  on one at 
baseline  
Patients in the adalimumab treatment group who already are taking a conventional  
immunosuppressive drug will continue that drug throughout the study  (in addition to the 
adalimumab) unless some contraindication to continuation arises .  Those for whom existing 
immunosuppressive therapy is deemed non -useful should discontinue it before entering the 
study . 
 
4.3.2  Conventional immunosuppression treatment group 
Patients randomized to conventional immunosuppression will be started as soon as possible on 
a conventional immunosuppressive drug, according to published guidelines,14 using one of the 
drugs in Table  5.  The study ophthalmologist  will select amongst the permissible drugs 
(methotrexate, mycophenolate or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to the 
patient ’s clinical situation. Initial and maximum dosing for antimetabolites and dosing for 
calcineurin inhibitors will be as outlined in Table 5 .  Because alkylating agents typically are not 
used in combination with another immunosuppressive drug, they will not be used in ADVISE , 
except possibly among those progressing to treatment according to best medical judgment .   
 Patients receiving no immunosuppressive agents at the time of enrollment  
• The initial immunosuppressive drug will be an antimetabolite (azathioprine, mycophenolate, or methotrexate) given at initial dose in Table 5 unless contraindicated  
 
 In the MUST Tr ial antimetabolites were overwhelmingly the initial choice for 
immunosuppression, and available data suggest similar efficacy (including a randomized trial 
comparing methotrexate to mycophenolate
70). Because of the differing side effect profiles, 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  34 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  allowing a ny of the three drugs will allow more patients to participate than choosing one drug 
alone but will not compromise the efficacy estimate of conventional immunosuppression, as all 
3 drugs have similar corticosteroid- sparing efficacy .   
 
Patients already on one immunosuppressive drug at enrollment will be treated based on 
the drug being received.   
• Patients on an antimetabolite will receive a calcineurin inhibitor  as directed in Table 5 
unless contraindicated  
• Patients on a calcineurin inhibitor will receive an antimetabolite  at initial dose in Table 5  
unless contraindicated.    
 
Because most patients treated with immunosuppression receive an antimetabolite first, this 
subgroup largely will consist of the addition of a calcineurin inhibitor.  A randomized trial of 
tacrolimus vs cyclosporine suggested similar efficacy for the two drugs ,35 so either drug can be 
chosen.  This approach mimics conventional clinical care.   
 
Selection of antimetabolite or calcineurin inhibitor 
As in the MUST Trial, the choice of antimetabolite and the choice of calcineurin inhibitor in the 
conventional arm will be made based on the patient’s clinical history by the clinician at the 
clinical center but used in a standard fashion.21 Initial and maximum dosi ng for antimetabolites 
and dosing for calcineurin inhibitors  will be as outlined in Table 5 below.  
Note:  Systemic immunosuppressive drugs other than those mentioned in this section are not 
permitted as study medications.  
 
 
 
  
 
 
Table 6.  Conventional immunosuppressive drugs in the ADVISE Trial  14,21 
Class  Generic name  Trade name  Initial dose  Max dose  
Antimetabolite  Azathioprine  Imuran  2 mg/kg/day  200 mg/day  
 Methotrexate*  Rheumatrex  15 mg/w eek 25 mg/w eek 
 Mycophenolate  CellCept  1 gm BID  1.5 gm BID  
     
Calcineurin inhibitor  Cyclosporine  Sandimmune  2.5 mg/kg BID  2.5 mg/kg BID  
  Neoral  2 mg/kg BID  2 mg/kg BID  
 Tacrolimus† Prograf  1 mg BID  3 mg BID  
     
* Orally or subcutaneously; with folate  
† Escalate every 2 to 4 weeks  to therapeutic blood level or maximum dose  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  35 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  4.4 Advancement of immunosuppressive treatment  
For patients who come in to the study with active uveitis, advancement of immunosuppression 
is required  if uveiti s is neither not controll ed or substantially improved such that it is expected to 
be inactive at the next visit  four weeks after initiating study -specified medications .  
 
Advancement of immunosuppression is also required if  uveitis reactivates during prednisone 
taper ing.  See section 4.5 for guidelines for managing uveitis reactivation during prednisone 
taperin g, which requires prednisone increase in addition to advancement of 
immunosuppression. As noted in section 4.5, if uveitis reactivates after achieving prednisone 
cessation, the decision of whether to advance immunosuppression should be made according 
to best medical judgment.  
 The general hierarchy for advancement of immunosuppression is  to (1) maximize the dose of  
current  immunosuppressive drug(s) as applicable; (2) add a new conventional 
immunosuppres sive drug at initial dose and maximize dose as applicable. Patients assigned to 
conventional immunosuppression may receive two conventional immunosuppressive drugs, an 
antimetabolite and a calcineurin inhibitor. Patients assigned to adalimumab may receive one 
conventional immunosuppressive drug.  If uveitis cannot be controlled at maximum permitted 
immunosuppression, patient will be treated per best medical judgment. Additional details are 
included in the ADVISE Manual of Procedures section 8.4 .  
    
4.5 Management of uveitis reactivation  
The guidelines for managing uveitis reactivation are summarized in tables 6a. Reactivation 
management guidelines :  Prednisone  and 6b. Reactivation management guidelines:  
Immunosuppression. 
 The prednisone dose to be used for uveitis reactivation will depend upon whether the 
reactivation occurs during the prednisone taper or after prednisone cessation.  If the uveitis 
reactivates during the prednisone taper, the dose of prednisone will  be at least doubled, up to  
the maximum allowed dose (1mg/kg/day up to 60 mg/day ), depending on the severity of the 
reactivation per table 6a.   If uveitis reactivates after achieving prednisone cessation, 
prednisone will be reinstated at a dose of at least 10 mg/day up to the maximum allowed dose 
(i.e., 1 mg/kg/day if < 60 kg or 60 mg/day if ≥ 60 kg), depending on the severity of the 
reactivation.  The study physician will determine whether to advance immunosuppression per 
best medical judgment.  
 
 As adalimumab is FDA -approved at only a single dose, advancement of immunosuppressive 
therapy will focus on the addition or increase in dose of conventional immunosuppressive agents for both treatment arms.  The advancement of conventional immunosuppressive 
agents will depend upon number and dose(s) of the current medications being used .   
 
For pa tients  on less than the maximum dose of a conventional immunosuppressive agent, it 
should be increased to the maximum dose in Table 5 , as applicable and tolerated.  For 
patient s on the maximum dose of a single immunosuppressive drug, a second agent from the 
other class should be added.  For patien ts on an antimetabolite, a calcineurin inhibitor will be 
added and vice versa.  For pa tients already on 2 immunosuppressive drugs at maximum 
doses, best medical judgment will be used, including changing one or both of the currently 
used immunosuppressive agents.   
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  36 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Although it might be argued that conventional immunosuppressive agents might be used 
initially at the maximum dose to avoid the dose escalation step, this alternative approach does 
not mimic clinical practice, whereas the use as outlined in Table 5 does.14  Furthermore, this 
approach minim izes the possibility of drug -related side effects, and many patients respond to 
the initial dose without need for dose escalation.16,71  For example, among patients who 
respond to treatment with methotrexate, the majority do so at a dose of 15 mg/week .71  For 
patients  assigned to convent ional immunosuppression requiring changes in the 
immunosuppressive agent for side effects, an attempt will be made (if possible) to change 
within class (e.g., a different antimetabolite); if not possible, the alternative class may be used, 
or if necessary best medical judgment.  These guidelines are presented in more detailed outline format in the Manual of Procedures section 8.5. 
 
If uveitis reactivates after achieving prednisone cessation, prednisone will be reinstated at a 
dose of at least 10 mg/day up to the maximum allowed dose (i.e.,  1 mg/kg/day if < 60 kg or 60 
mg/day if ≥ 60 kg), depending on the severity of the reactivation.  The study physician will 
determine whether to advance immunosuppression per best medical judgment.  
 
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  37 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
 
Table 7.  Reactivation management guidelines  
Table 6a.  Reactivation management guidelines:  Prednisone  
Scenario  Action for prednisone dose  First opportunity to 
taper   
(2 weeks after prednisone 
increase)*  Second opportunity to taper   
(4 weeks after 
prednisone increase)  
Reactivation 
during prednisone taper  If current dose ≥ ½ maximum allowed 
dose, increase to maximum allowed dose  
If current dose < ½ maximum allowed 
dose, increase to between double 
current dose and maximum allowed dose depending on severity  Controlled: Taper  
Not controlled:  
If increased dose is not maximum allowed dose, increase to maximum allowed dose  Controlled: Taper  
Not controlled:  Taper  
but not  below 7.5 
mg/day  until uveitis is 
inactive  
Reactivation after 
tapered off prednisone  Reinitiate prednisone at dose of at least 10 mg/day up to the maximum allowed dose (i.e., 1 mg/kg/day if < 60 kg or 60 mg/day if ≥ 60 kg), depending 
on the severity of the reactivation  Controlled:  Taper  
Not controlled: Treat per 
best medical judgment  Controlled:  Taper  
Not controlled:  Treat 
per best medical 
judgment  
* If the study ophthalmologist does not expect the uveitis to be controlled within 2 weeks of the prednisone increase, 
then an initial course of 4 weeks of prednisone can be prescribed. The first assessment of activity would occur at 
the next scheduled visit (i.e. in 4 weeks).    
 If the study ophthalmologist expects the uveitis to be controlled within 2 weeks of the prednisone increase, then 
the corticosteroid taper can be automatically initiated at 2 weeks without a clinic visit.  The first assessment of  
activity would occur at the next scheduled visit (i.e. in 4 weeks)  
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  38 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
Table 6b.  Reactivation management guidelines:  Immunosuppression  
Treatment 
assignment  Scenario  Immunosuppression 
management  
Conventional 
immunosuppression  1 conventional IMT† at initial dose  Increase to maximum dos e‡ 
 1 conventional IMT at maximum dose ‡ Add 2nd  conventional IMT from 
alternative class†† at initial dose  
 1 conventional IMT at maximum dose ‡, 
2nd conventional IMT at initial dose  Increase 2nd conventional IMT to 
maximum dose ‡ 
 2 conventional IMTs at maximum 
doses ‡ Treat per best medical judgment  
   
Adalimumab  Adalimumab only  Add conventional IMT¶ 
 Adalimumab & conventional IMT initial 
dose  Increase conventional IMT to 
maximum dose ‡ 
 Adalimumab & conventional IMT at 
maximum dose ‡ Treat per best medical judgment  
† Conventional immunomodulatory therapy (immunosuppressive therapy) drug  
‡ Maximum dose = maximum dose of antimetabolite or dose resulting in therapeutic blood level for tacrolimus, up 
to maximum dose per table in section 8.3.2.1. Note: Cyclosporine has only one dose.  
†† If on an antimetabolite, add a calcineurin inhibitor; if on a calcineurin inhibitor, add an antimetabolite.  
¶Antimetabolite preferred; either class acceptable  
 
 
 
4.6 Monitoring for t oxicity of immunosuppressive drugs   
Patients will be monitored for potential toxicities of adalimum ab or conventional 
immunosuppressive therapy/therapies using the schedule described in the Trial’s follow -up 
schedule (Table 2), i.e., complete blood count and chemistry panel including creatinine and 
liver enzymes will be conducted at every study visit and monitoring and prevention strategies 
will be implemented as detailed in Table 7. Potential Risks of Therapy .  As applicable, 
additional monitoring studies should be carried out per routine care.14 When potential toxicities 
are encountered, modification of therapy, including dose reduction or discontinuation as 
clinically appropriate, should be done along the lines indicated in published guidelines.14 
 
4.7 Discontinuation of treatment within the assigned treatment arm  
4.7.1  Discontinuation for toxicity  
As applicable, when toxicity cannot be managed through modification of treatment regimen, assigned treatment may be discontinued and participant managed according to best medical 
judgment.  
 
ADVISE PROTOCOL  1.3 (12 OCT 2020)  Treatment schedule │  39 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  4.7.2  Discontinuation for pregnancy  
If a participant becomes pregnant, methotrexate and mycophenolate mus t be discontinued as 
methotrexate is known to increase the risk of spontaneous abortion and malformations and 
mycophenolate is known to increase the risk of malformations.   Consideration should be given 
to discontinuation of azathioprine, cyclosporine, tacrolimus, and adalimumab. Participants should be managed according to best medical judgment.
72  
 
4.8 Ancillary therapy   4.8.1  Regional corticosteroid Injections  
The MUST Trial demonstrated that the majority of patients with uveitic macular edema require 
supplemental regional corticosteroid injections (either periocular or intravitreal) to improve the 
macular edema, but that they typically need only one or two injections .
73  Therefore, participants 
in the ADVISE Trial with uveitic macular edema will be permitted a regional corticosteroid injection within the first 2 months, if needed, and a second injection during months 6 to 8 (if 
needed) for persistent macular edema (to meet  patients’ clinical needs without contaminating 
key outcomes).  Acceptable regional injections are: 1) periocular triamcinolone acetonide 40 
mg, 2) intravitreal triamcinolone acetonide 4 mg (Triesence® [Alcon Laboratories, Inc., Fort 
Worth, TX] preferred i f available due to its being preservative free for intravitreal use). or 3) the 
dexamethasone intravitreal pellet (Ozurdex  ®, Allergan, Inc., Irvine, CA).
5474   If a participant is 
given an injection during the first 2 months of the trial, the dose of prednisone should 
not go below 7.5 mg/day (or if already <7.5 mg/day, should not be tapered further) until 3 months after the injection, as the primary outcome only can be ascertained 3 months after an injection . Allowing the limited use of regional corticosteroid injections for uveitic 
macular edema is necessary for proper clinical care, and the restrictions on their use will permit evaluation of the trial’s outcomes.  
 
4.8.2  Topical corticosteroids  
• Adjunctive use of high doses of topical corticosteroids (up to one drop hourly of 
prednisolone acetate 1%, prednisolone sodium phosphate 1% or loteprednol 
etabonate 0.5%, or one drop six times daily of difluprednate 0.05%) is permitted for 
up to two weeks after anterior chamber uveitic activity is first observed.  
• Upon quiescence of the anterior chamber inflammation, topical corticosteroids 
should be tapered  
• Maintenance therapy of not more than  prednisolone acetate 1% or loteprednol 
0.5% three times daily or difluprednate 0.05% one drop daily is permitted. 
• Failure to control anterior chamber inflammation using this approach should be addressed with systemic corticosteroids and immunosuppression. 
• Discontinuation of such therapy, when feasible, is encouraged  
 
4.8.3  Non-corticosteroid ophthalmic medications  
These may be used according to best medical judgment. 
 
4.8.4  Systemic medications other than corticosteroids and i mmunosuppressive 
drugs  
These may be used according to best medical judgment.  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Treatment schedule │  40 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
4.8.5  Treatment monitoring  
Treatment will be monitored for consistency with the treatment guideline by a member of the 
MTQAC,21 MTQAC  will monitor treatment patterns as revealed in the data stream, site visits, 
etc., and investigate inconsistencies with treatment guidelines , providing remediation as 
appropriate.   
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Study treatment procurement  │ 41 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  5. Study treatment procurement  
 
Adalimumab will be donated by AbbVie (Chicago, IL); distribution to clinical centers is described 
in the manual of procedures.  Prednisone and conventional immunosuppressive study 
treatments are not provided by the study and will be obtained per standard care.   
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Possible side effects and complications of study treatments  │ 42 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  6. Possible side effects and complications of study treatments  
Although there are potential risks associated with systemic corticosteroids and 
immunosuppression, they typically are reversible with dose reduction or discontinuation of the 
drug.  The MUST Trial and Follow -up Study demonstrated that there was essentially  no 
increased risk of these events compared to treatment with a strictly regional therapy, the 
fluocinolone acetonide implant, with the one exception of a greater use of antibiotics among participants receiving systemic therapy.
15,22,23,24 Hence, with appropriate use, these risks can be 
minimized .  Thus, the risks associated with participation in the ADVISE Trial are expected not to 
be greater than those associated with clinical care for patients with these uveitides. Possible 
side effects of the randomly assigned study treatments and of corticosteroids ar e summari zed in 
Table 7 . 
Patients in ADVISE Trial will receive oral corticosteroids for treatment of uveitis, as they would 
in clinical care.  The potential side effects of oral corticosteroids include water retention, weight gain, headache, muscle weaknes s, loss of muscle mass, face puffiness, growth of facial hair, 
easy bruising, acne, rounding of the upper back, irregular menstrual periods, insomnia, mood 
swings, increased energy, personality change, hypertension, hyperglycemia, and 
hypercholesterolemia.   Oral corticosteroid therapy may lower resistance to infections, make 
infections harder to treat, slow wound healing, and increase the risk of osteoporosis.  Aseptic necrosis of bone is a rare but serious complication.  For persons already at risk of cong estive 
heart failure, corticosteroids can increase the risk. Side effects occur more often with longer 
treatment and with higher doses, and typically resolve when dosage is lowered or treatment is 
discontinued.  As noted previously , serious complications such as these are very rare, 
particularly when appropriate management is used, as was done in the MUST Trial, including aggressive tapering of prednisone to a dose < 7.5 mg/ day
15,22,23,24  In the MUST Trial and Follow -
up Study, there generally was no significant increase is systemic side effects with systemic 
therapy  through 7 years of follow -up.15,22,23,24  Ocular side effects seen in the eyes of patients 
with uveitis treated with systemic corticosteroids include the need for cataract surgery at ~6%/year, ocular hypertension at 3%/year, and glaucoma at 1.3%/year.
15   Typically, these side 
effects are lower than with alternatively local therapies, as was demonstrated in the MUST 
Trial.15,22,23,24   
In addition to corticosteroids, pa tients  in the ADVISE Trial will r eceive immunosuppressive 
agents, either conventional (small molecule) drugs or the biologic adalimumab.  For many of these diseases, immunosuppression has been shown to produce superior outcomes.
15,17,18,19,20 
The eligibility criteria select  patients for whom immunosuppression is indicated, so that 
patients are not expected to  experience any greater risk than would be seen with clinical care.  
Conventional immunosuppressive agents with activity against uveitis  that will be used in 
ADVISE are the antimetabolites, azathioprine (AZA), methotrexate (MTX), and myc ophenolate 
mofetil (MMF); and the calcineurin (or T cell) inhibitors, cyclosporine (CSA) and tacrolimus 
(TAC).14  Because of the potential increased risk of cancer associated with alkylating agent use, 
and because they are not used in conjunction with other immunosuppressive drugs, cyclophosphamide and chlorambucil will not be used in the trial,
43,44,45,46,47 unless the patient 
suffers sufficient relapses that (s) he is treated with b est medical judgment.  Each of these 
agents is associated with its own spectrum of potential systemic side effects.  Side effects 
associated with these medications that are medically important and expected to occur with detectable frequency during the trial are described below.
14 The ADVISE Trial will conduct 
surveillance for these potential risks in a protocol -directed manner that approximates medical 
care (see Table 7 ).  However, the side effects mentioned below did not occur with higher 
frequency in the systemic therapy group of the MUST Trial than in the strictly local therapy 
implant group.15,22,24 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Possible side effect s and complications of study treatments  │ 43 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Bone marrow suppression:  a) Reversible neutropenia – which may occur with AZA, MTX, MMF, 
TAC – will be evaluated over time as the cumulative proportion having a total white blood cell 
(WBC) count 2500 cells/μL or fewer, which still is above the level for an increased risk of 
infection, and is a common indication for interruption of therapy.  Change in WBC count from 
baseline and use of granulocyte stimulatory factors also will be noted; b) Reversible thrombocytopenia – which may occur with AZA, MTX, MMF, TAC – will be evaluated over time 
as the  cumulative  proportion having a plat elet count 100,000/μL or fewer, which is a common 
indication for suspension of therapy.  Hemorrhagic events and requirement for platelet transfusion or other treatments for thrombocytopenia also will be noted; c) Reversible anemia – 
which may occur with AZA, MTX, MMF, CSA, TAC – will be evaluated over time as the 
cumulative proportion having a hemoglobin level <10 g/dL, a level often considered clinically 
meaningful.  Use of transfusions and of erythropoietin also will be noted; and the occurrence of 
myelodysplasia will be noted if confirmed in medical records.  
Reversible hepatotoxicity  -- which may occur with AZA, MTX, MMF, CSA, and TAC --  will be 
evaluated over time as the cumulative proportion with any of the following, verified in medical 
records: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater 
than two times the upper range of normal confirmed by repeat testing; OR discontinuation of an 
immunosuppressive agent due to hepatotoxicity.  Cases of persistent elevation of AST  and/or 
ALT after discontinuation of the offending agent will be noted.   
Reversible nephrotoxicity  -- which may occur with CSA and TAC -- will be evaluated over time 
as the cumulative proportion with:  serum creatinine level elevated 30% above baseline or  to a 
level of 1.5 mg/dL or higher OR discontinuation of an immunosuppressive drug for renal toxicity.  
Persistent renal insufficiency will be noted.  
Pregnancy risks :  MTX and MMF are associated with increased risk of first trimester pregnancy 
loss and congenital malformations; women of child bearing potential and men taking MTX are 
advised to use adequate birth control during the trial, and especially if taking these medications.  
Infection:  even without an increased risk of leukopenia among pa tients in th e (unmasked) MUST 
Trial on systemic therapy, there was an increased use of antibiotics for infection.15,22,23,24 
However, there were no long- term sequelae from these infections, and no increase in the risk of 
hospitalization for infection.15 Patients  will be queried about infections at every visit, and medical 
records reviewed as necessary, to monitor f or infections.  Hospitalization data also will be 
collected.  In non- uveitis use (e.g. , transplants) some immunosuppressive regimens may 
increase the risk of severe opportunistic infections (e.g. , progressive multifocal 
leukoencephalopathy), which can have serious consequences, including death.  Although there 
were no such events in the MUST Trial, because of their rare nature, their possible occurrence 
in the ADVISE Trial or routine clinical practice using these drugs cannot be excluded.   
Additional recognized potential complications of potent immunosuppressive therapy will be 
deemed to be present when diagnosis is confirmed by medical records.  These conditions 
specifically will include a diagnosis of any of the following conditions (if not present at baseline):  
a) liver cirrhosis; b) interstitial pneumonitis; c) possibly malignancy (drug- specific); d) end- stage 
renal insufficiency .   
In addition to these small molecule immunosuppressive agents, the anti -TNF-α biologic agent 
adalimumab will be used.33 The most common adverse reaction of adalimumab is redness, 
itching, pain, or swelling at the injection site, reported in 20% of patients.  Other less common 
adverse events include: increased risk of infections, particularly tuberculosis, fungal infections, 
and herpes zoster. Patents randomized to adalimumab will be instructed not to get any live 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Possible side effects and complications of study treatments  │ 44 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  vaccines.  O ther uncommon potential adverse effects include gastrointestinal symptoms such 
as nausea, vomiting, abdominal pain, or diarrhea; reversible bone marrow suppression; and 
reversible hepatotoxicity.  Other rare adverse events include: development of anti -adalimumab 
antibodies and a lupus erythematosus -like syndrome, and a worsening of demyelinating 
disease, such as multiple sclerosis. All patients enrolled in the ADVISE Trial will have 
tuberculosis testing with either an interferon -γ release assay test, such as the Quantiferon- gold 
test and testing for active hepatitis B or  C infection75,76 prior to enrollment.  Active tuberculosis 
and untreated latent tuberculosis  and untreated active hepatitis B or C infectio n are exclusions 
to participation.  Because of the increased risk of multiple sclerosis in patients with pars planitis 
and undifferentiated intermediate uveitis,11,12 all potential participants with these two diseases 
will undergo neuro- imagi ng with a gadolinium enhanced MRI scan and patients with evidence of 
possible demyelination are excluded from the trial .   
Use of the following medications are prohibited during the trial for safety reasons  
• Live vaccines  
• Substrates for the multidrug efflux transporter P -glycoprotein or the organic anion 
transporter proteins (OATP) and for which elevated plasma concentrations are associated with serious and/or life threatening events, e.g. bosentan, dabigatran 
etexilate and aliskiren.  
• Products containing Hypericum perforatum (St John´s Wort) to avoid risk of interaction 
with tacrolimus that lead to either a decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus, or an increase in blood concentrations of tacrolimus and risk of tacrolimus  
 
ADVISE PROTOCOL 1.3 (12 OCT 
2020)  Possible side effects and complications of study treatments │  45 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Table 8.  Potential risks of therapy  
Treatment  Group affected  Systemic  Monitoring & Prevention Strategy  
Corticosteroids  Both groups  Hyperglycemia  History; CMP testing  
  Hypertension  History; BP measurement  
  Osteoporosis  Routine monitoring/ data collection  
  Hyperlipidemia  Routine monitoring/ data collection  
  Infection  Routine monitoring/ data collection  
  Cardiovascular Disease  Routine monitoring/ data collection; 
Monitor risk factors (per above)  
    
  Cataract  Slit lamp examination/Eye Exam  
 
 
 
  Intraocular Pressure 
Elevation and Glaucoma Eye Examination  
Adalimumab  Adalimumab  Infection  Pre-randomization tuberculosis  and 
hepatitis B and C  testing; Routine 
monitoring/ data collection. Live vaccines 
should not be given.  
  Worsening of m ultiple 
sclerosis MRI of patients with intermediate uveitis 
at BL; Routine monitoring/ data 
collection  
  Injection Site Reaction*  Routine monitoring/ data collection  
  Bone marrow toxicity*  CBC testing  
  Hepa totoxicity*  CMP testing, pre-treatment Hepatitis 
panel  
Methotrexate  Conventional  Bone marrow toxicity*  CBC testing  
  Hepato toxicity*  CMP testing, pre -treatment Hepatitis 
panel  
  GI intolerance*  History/Routine monitoring  
  Teratogenicity/ 
Miscarriage  Birth control use for women and men  
  Alopecia*  Routine monitoring/ data collection  
    
Mycophenolate  Conventional  Bone marrow toxicity*  CBC testing  
  Hepa totoxicity*  CMP testing, pre -treatment Hepatitis 
panel  
  GI intolerance*  History/Routine monitoring  
  Teratogenicity  Birth control use 
  Possibly PML (disputed)  History/Routine monitoring  
ADVISE PROTOCOL 1.3 (12 OCT 
2020)  Possible side effects and complications of study treatments │  46 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  Treatment  Group affected  Systemic  Monitoring & Prevention Strategy  
 
Azathioprine  Conventional  Bone marrow toxicity*  CBC testing  
  Hepat otoxicity*  CMP testing, pre -treatment Hepatitis 
panel  
  GI intolerance*  History/Routine monitoring  
    
Cyclosporine  Conventional  Hypertension*  History; BP measurement  
  Renal insufficiency*  CMP testing  
  Tremor/paresthesia*  History/Routine monitoring  
  Hirsutism*  History/Routine monitoring  
  Gingival hyperplasia*  History/Routine monitoring  
    
Tacrolimus  Conventional  Hypertension*  History; BP measurement  
  Renal insufficiency*  CMP testing  
  Tremor/paresthesia*  History/Routine monitoring  
  Hyperglycemia*  History; CMP testing  
  Interactions with products 
containing Hypericum 
perforatum  Products containing Hypericum 
perforatum (St John´s Wort).may not 
used during the study  
      
*Usually reversible with dose adjustment or cessation of therapy   
CMP=complete metabolic panel; BP=blood pressure; CBC=complete blood count  
 
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Safety reporting of advers e events  │ 47 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  7. Safety reporting of adverse events  
7.1 Adverse events   
Adverse events (AEs) and  complications of study treatment  will be submitted to the CC.  As 
described in section 7.2, all serious adverse events (SAEs) will require expedited reporting to 
the CC for immediate review by the CC Safety Officer  who will determine any further actions 
required including whether the event requires expedited review by the Data and Safety 
Monitoring Committee ( DSMC) Safety Officer .  The CC and DSMC Safety Officers will make  
recommendations to the DSMC  as to any actions  that may be needed.   
 
7.2 Serious adverse events 
An SAE is an adverse event that results in one of the following outcomes: death, a life-
threatening adverse drug experience, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity, or congenital anomaly/birth 
defect. Also, important medical events that may not result in death, be life- threatening, or 
require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention (treatment) to prevent any of the outcomes previously listed in 
this definition.  
 Clinical centers will report all SAEs  to the CC expeditiously  regardless  of the relationship to 
study  treatment.  When an investigator or clinical center staff member becomes aware of an 
SAE, it will be reported to the CC within 72 hours (within 24 hours for UK clinics only*) with 
follow up reporting until the event is terminated.  The SAE report will include an assessment 
by the clinical investigator at the managing clinical center as to the likelihood whether the 
event is related to treatment.  Upon receipt at the CC, the SAE report  will be sent to the CC 
Safety  Officer  for immediate re view and determination as to whether  the event  meets  the 
criteria  for a safety  report  and whether  expedited review  by the DSMC  Safety Officer  is 
warranted.   
 All serious  and unexpected events  poss ibly related to study treatment  will be reported  as safety  
reports  to the NEI project  officer,  the pharmaceutical  supplier  (where appropriate),  applicable 
regulatory agencies (.e.g., FDA and Health Canada),  and all clinical centers in accordance with 
applicable regulations.  The CC  and clinical centers  will submit  all safety  reports  as expedi ted 
reports  to their Institutional Review Board s (IRBs ).  Reports  of SAEs not deemed  to be 
unexpected will be submitted to the CC’s  IRB, to the IRB of the clinical center in which  the 
event was  reported,  as well as to any other  study  center  IRBs  which  require such re ports.  
 
*For compliance with the CT3 directive (2011/C 172/01) (Section 4.3.1): “Communication from the 
European Commission — Detailed guidance on the collection, verification and presentation of adverse 
event/reaction reports arising from clinicaltrials on medicinal products for human use   
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Sample size and statistical methods  │ 48 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx   
8. Sample size and statistical methods  
 
8.1 Hypotheses  
The primary hypothesis is that adalimumab will be superior to conventional immunosuppression 
for corticosteroid sparing, as determined by the proportion of participants that achieve the 
primary outcome, namely inactive uveitis and prednisone < 7.5 mg/day for 2 visits >28 days 
apart by 6 months of follow -up.  The 6 -month time frame was chosen to allow sufficient time to 
observe the primary outcome regardless of the patient’s pre dnisone dose  at randomization and 
is likely to be more robust to imbalances . 
 
Secondary hypothesis are that adalimumab will be superior to conventional immunosuppression 
for: 
• Corticosteroid sparing (inactive uveitis and prednisone < 7.5 mg/day for 2 visits >28 
days ) apart by one year of follow -up  
• Prednisone discontinuation (inactive uveitis for 2 visits > 28 days after discontinuation of 
prednisone) by one year .   
 
Furthermore, we hypothesize that these benefits will be accomplished with no increase in ocular 
or systemic adverse events (other than injection site reactions) with adalimumab, and that both approaches will produce similarly visual acuity and incidences of uveitic complications .     
 
8.2 Sample size  and power calculations  
Sample size is calculated for  the primary comparison of corticosteroid- sparing treatment 
success (inactive uveitis and prednisone <7.5 mg/day for 2 consecutive visits >28 days apart ) at 
6 months. Based on the preliminary data from the VISUAL III Study, we estimate that 
adalimumab will  be successful in achieving the primary outcome in 75% of patients across all 
strata.  The success of conventional small molecule immunosuppression varies according to the type and number of treatments.  Based upon the Mount Sinai and MUST Trial data, we estimate that 75% of the participants will be in the stratum of no prior immunosuppression and 25% will 
be on one immunosuppressive agent at enrollment.
16  Based on the SITE data, the estimated 
success rate for antimetabolites is 55% and for calcineurin inhibitors 40%.28,29,30,31  Patients in 
the no immunosuppression stratum will receive antimetabolites, whereas those in the one 
immunosuppression stratum will largely receive calcineurin inhibitors.  Therefore, success rates of 55% and 40% are estimated for the no and one immunosuppressive agent strata, 
respectively.  Based on the estimated stratum proportions and corresponding success rates, the 
overall conventional immunosuppression success rate is estimated to be 51%. In the MUST 
Trial, the loss to follow -up was 6% at 2 years.  In order to be conservative, we will assume a 
10% loss to follow -up in each group and that all individuals were lost prior to observing a result. 
Under these assumptions, a sample size of 222 (111 participants per treatment group) provides 90% power to detec t significant differences between the 2 groups if the underlying true 
proportions are 51% vs. 75% (46.1% vs. 67.5%, respectively, after adjusting for the loss to follow -up), assuming a two- sided type I error of 0.05. VISUAL I and II, while not appropriate for 
estimation of corticosteroid- sparing due to a rapid taper, do provide some estimates of the 
ability to discontinue prednisone, which can be estimated as 50%.  Based upon data from Mount Sinai and the MUST Trial, estimates of the discontinuation rates for standard 
immunotherapy range between 11% -35%. A sample size of 222 provides 80% power to detect 
an increase in the secondary outcome of discontinuing prednisone while controlling the uveitis 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Sample size and statistical methods  │ 49 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  by 1 year from 30% to 50% (estimated from VISUAL I and II data), assuming a two- sided type I 
error of 0.05.  
 
 
8.3 Statistical analysis plan 
A detailed description of the statistical principles and analyses is provided in the Statistical 
Analysis Plan.  The primary analyses will be based upon assigned treatment and will include all 
available data, following the principles of intention to treat, with additional sensitivity analyses 
based upon treatment received.  The primary analyses will include adjustment for randomization 
strata (immunotherapy use and prednisone dose).  Additional analyses that are unadjusted or 
are adjusted for potential confounders including but not limited to age, gender, race, and uveitis 
class (e.g. , intermediate, posterior, panuveitis) will also be performed as secondary analyses   
Robust standard errors will be computed using statistical program -based approaches when 
available and a bootstrap with the individual as the sampling unit when a pre- programmed 
approach is not available.  
 
The primary goal of the trial is to establish whether adalimumab is superior to conventional immunosuppression for corticosteroid- sparing in the treatment of individuals with intermediate, 
posterior, or pannuveitis. The analysis will focus on the cumulative proportion with a corticosteroid sparing success. Once a success h as been achieved, then it will remain fixed for 
that individual thereafter.  A more standard time to event analysis, which allows for censoring 
due to loss to follow -up, was considered.  However, because the time required to taper 
prednisone to < 7.5 mg/day depends substantially on the initial/enrollment dose, small imbalances at baseline could influence greatly such analyses despite stratification. Therefore, 
time to event analyses will be used as sensitivity analyses.  The 6 -month time frame was 
chosen to  allow sufficient time to observe the primary outcome regardless of the participant’s 
prednisone dose at randomization and is likely to be more robust to imbalances.   Multiple 
imputation will be used to address missing data due to missed interim visits  and loss to follow -
up. 
 
Since a minimum of two follow -up visits must occur prior to achieving a corticosteroid success 
and prednisone must be tapered, the first outcome evaluation will occur at 2 months (V03) and 
will continue for every visit thereafter.  Modeling will focus upon the period between 6 months 
and 1 year due to the potential for imbalances in the tapering patterns described above.  
Generalized estimating equations (GEE) will be used to fit logistic regression models comparing 
the two treatment  groups over time while accounting for the correlation between replicate 
measurements.  A saturated mean structure including visits starting at 6 months (V07 -V10), 
treatment, and visit by treatment interaction terms plus the two stratification variables (baseline 
immunotherapy and initial prednisone dose) will be used.  The 6 -month visit by treatment 
interaction will be used to assess the primary outcome.  An unstructured correlation matrix will 
be used to model the within- individual repeated measurements.  Alternate correlation structures 
(e.g., exchangeable) will be explored if the unstructured covariance matrix is unstable. This 
model estimates the relative odds of corticosteroid- sparing for adalimumab vs conventional 
immunosuppression. A standardized estimator, which allows for covariate adjustment, will be 
used to compare the absolute (as opposed to relative) difference in proportions at each 
timepoint based upon the logistic model described above and a bootstrap estimate of the 95% 
confidence intervals.   This estimator has the advantage of providing a consistent estimate even 
if the means model is mis -specified.77,78 Analyses of the secondary hypotheses will follow the 
same data management and analysis structure.  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Regulatory and ethical issues  │ 50 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  9. Regulatory and ethical issues  
 
9.1 Recruitment  and informed consent procedures 
Patients will be recruited at each  clinical center by clinicians  who will present the opportunity to 
participate in the trial, discussing the potential risks and benefits in the patient’s particular 
circumstances.  Patients  choosing to participate will give written consent.  Adolescents and their 
parent or legal guardian will give written assent  or consent  according to the guidelines of the 
clinic’s governing IRB.      
 
A detailed, IRB -approved, informed consent document will be provided, and the patient will be 
provided ample opportunity to review it.  Study staff will make themselves available to answer any questions potential participants will have.  Anonymous data will be collected regarding non-
participants in compliance with CONSORT guidelines, so as to permit those reviewing the results of the study to know how many people did not enroll, and why they did not enroll.  
Clinical center consent forms are based on prototypes prepared by the CC and approved by the 
CC’s IRB, th e Johns Hopkins University Bloomberg School of Public Health IRB Office.  The 
prototype consent, written at an approximately 9 th grade reading level as rated by word 
processing software, is distributed to the clinical centers.  Although clinics may rearran ge 
information and modify language of the prototype to conform to local IRB templates and 
guidelines, deletion of information considered by study leadership to be essential to an informed 
consent process is not permitted.   For the ADVISE Trial, as in the MUST Trial, consents will be 
approved by all governing IRBs and will be required to include these key elements:  1) the 
purpose of the study; 2) selection of participants; 3) study visit schedule and study procedures; 
4) involved treatments; 5) risks associated with study procedures, uveitis, and uveitis 
treatments; 6) potential benefits of participation; 7) the voluntary nature of participation; 8) 
assurances that the patient’s treatment will not suffer if he or she declines enrollment or enrolls, 
but subsequently withdraws consent; 9) the names and whereabouts of contact persons; 10) 
explanation of costs for which the patient or patient’s insurer will be responsible and costs which 
will be paid for by the study (i.e., procedures and treatments that are req uired for the patient’s 
clinical care will be charged to patient’s insurance and patient is responsible for any co- pays; 
procedures done for study purposes only will be paid for by the study)  11) steps taken to 
protect patient confidentiality; 12) payments to assist with the costs of participation (e.g. , 
parking, transportation); 13) t hat short -term care will be arranged if the patient is injured as a 
result of participation in the study but that there is no plan for NIH or the institution to pay for 
such care; and 14) all other elements required by applicable government regulations.  At the 
beginning of each study, as part of clinic certification, the CC reviews each clinic’s IRB approved 
consent to assure that each local consent statement retained the req uired information.   
 
Over the course of the study as modifications to the consent are required, the CC revises the 
prototype consent and, after Johns Hopkins University Bloomberg School of Public Health IRB Office approval has been obtained, distributes the revised prototype to clinics with instructions 
for revising their local consents.  The CC tracks clinics’ IRB approvals for consent revisions, 
maintains an archive of clinics’ IRB -approved consents, and monitors IRB approvals to ensure 
approvals remain current.  Enrollment or conduct of study follow -up, absent the necessary IRB 
approvals, is not permitted. Site visits to clinics include a review of IRB approvals, of 
correspondence with the local IRB, and of consent documents signed and dated by individual 
patients and witnessed by clinic personnel.  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Regulatory and et hical issues  │ 51 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  9.2 IRB/Protection of human subjects  
This protocol will be submitted to the IRB of participating centers for review and approval.  
Clinics may not recruit patients into the ADVISE Trial prior to approval of this protocol by their 
governing IRB.  All ADVISE Trial patients must sign a consent statement and medical record 
release form as well as HIPAA – complaint privacy practices acknowledgment prior to 
participation in the study.  
Surveillance of uveitis and treatment complications is conducted throughout the study; any such 
complications encountered are managed by the best medical judgment of the treating 
ophthalmologist .  These events are recorded on study data forms and are submi tted to the CC. 
Summaries of these data are reviewed by the DSMC at each meeting.  Important, serious, or unusual adverse events require expedited reporting to the CC and are reviewed by the CC Safety Officer, who makes the determination as to whether the event meets the criteria for a 
safety report and whether expedited review by DSMC Safety Officer is warranted.  The CC 
Safety Officer follows all serious adverse events through resolution.  All serious and unexpected 
events possibly related to uveitis treatment will be reported as safety reports to the NEI project 
officer, the FDA, the pharmaceutical supplier (where appropriate), and all clinical centers in 
accordance with FDA regulations.  The CC and clinical centers will submit all safety reports as 
expedited reports to their IRBs.  Reports of serious events not deemed to be unexpected will be submitted to the CC IRB, to the IRB of the clinical center in which the event was reported, as 
well as to any other study center IRBs, which require such reports.  
 Confidentiality of patient data will be maintained in accordance with legal regulations.  Protected 
health information (PHI)  not be transmitted to the CO, CC, RC, or to other ADVISE sites .  PHI 
collected for study purposes, possibly including name, social security number, address, and other such personal data will be kept solely at the clinical center where the patient receives 
her/his clinical care and will be kept in a secure location.  A dataset limited so as to contain a 
minimal amount of protected health information –that required to make the data useful for 
accomplishing the purposes of the ADVISE Trial– may be disclosed, as needed,  to collaborating 
ADVISE sites and the NEI, as will be stated on a study privacy acknowledgment form signed by 
the participant at the time of enrollment.  Also included in the privacy acknowledgment is the 
statement that representatives of NEI, the Institutional Review Boards, and CC may see 
identifying information while reviewing study records.  This privacy acknowledgment will be designed to conform with specifications of HIPAA regulations, and any other relevant regulations, as approved by the local governing authorities invested with oversight of HIPAA 
regulations at each participating site.  Clinically relevant information from the study may be 
placed in the patient's medical record.  Release of protected health information to any other 
persons or organizations will require additional written consent of the patient affected, except as 
required by law.  
 
9.3 Data and Safety Monitoring Committee  
Trial monitoring will be conducted by an independent DSMC, appointed as advisory to the 
Executive Committee (EC) and the NEI.  The DSMC is  responsible for review of efficacy and 
safety data, policy and ethical issues, and study performance.  The DSMC is composed of  two 
ophthalmologists, one rheum atologist,  two biostatistician s, and an ethicist; other members may 
be added as deemed appropriate by the ADVISE Executive Committee (EC) and the NEI.  One 
of the physician members of the DSMC , will s erve as the DSMC Medical Safety Officer to 
review individual events or summary safety data between DSMC meetings, as deemed necessary by the CC Medical Safety Officer.  Treatment effects monitoring, including formal 
interim analyses, will be performed by the CC and presented to the DSMC.  The frequency and 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Study implementation  │ 52 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  type of analyses and evaluation is determined by the ADVISE Trial EC, NEI, and DSMC, with a 
minimum of at least two meets, typically one face -to-face and one conference phone call 
meeting , of the DSMC per year.  The policies and procedures for the DSMC analyses and 
deliberations are modeled on those we have used for other NEI -sponsored trials.  The primary 
focus of the DSMC analyses will be on the comparison of the treatment groups with res pect to 
safety and efficacy measures, which will include, but not be limited to, successful corticosteroid 
sparing, measures of visual acuity, quality of life, uveitis activity, uveitis complications, ocular 
and systemic adverse events, etc.  Presentation of the statistical methods that are used will be 
made by selected members of the Statistical Advisory Committee to the DSMC .  The DSMC will 
not be masked.  The DSMC may make recommendations to modify the protocol or to terminate the trial if there is early  evidence of benefit or harm associated with one of the treatments.  
Summaries of DSMC reviews and recommendations  are submitted to the CC and to each 
clinical center’s IRB for review.  
 
Performance monitoring will include comparisons of enrollment, baseline variables, protocol  
deviations, and missing data between clinics. Clinic performance data will be presented at  
DSMC , Steering Committee , and Research Group meetings.  
 
 
10. Study implementation  
 
10.1 Study organization  
The ADVISE Research Group (RG) consists of participating clinical centers  and three resource 
centers:  the CO, the CC, and the RC).  The resource centers are funded via U10 cooperative 
agreements and the clinical centers via subcontracts with the CC.  The responsibilities of the 
clinical and resource centers and the committee structure for the ADVISE Research Group are 
detailed in the ADVISE Manual of Procedures.  
 
10.1.1  Characteristics of target population and recruitment strategies  
The population of interest is that to which results of the trial will be generalized.  Recognizing that ethical considerations limit participation to those who agree to become clinical trial subjects, 
we aim to recruit a study population reasonably similar to the population of interest, which is the 
group of patients for whom immunosuppressive drugs would be prescribed as a treatment for intermediate, posterior and panuveitis.  This objective will be accomplished by recruiting 
subjects from clinical practices that administer immunosuppr essive therapy for eye diseases on 
a frequent basis.  The distribution of uveitis disease types in the recruited study population for 
ADVISE is likely to resemble the  distribution of uveitis disease types for the population recruited 
for the MUST Trial which is provided in Table 1 . 
 
10.2 Quality assurance  
10.2.1  Medical Therapy Quality Assurance Committee  
The MTQAC  is a committee of 3 experienced uveitis experts, involved in management of the 
ADVISE Trial, but not in managing patients enrolled in the trial. The primary role of the MTQAC 
is to ensure adherence to the assessment of activity and treatment guidelines. Additional details 
of each type of monitoring are provided below.  During the design phase, members of the 
MTQAC will work with the CC to design forms to capture the details required to assess 
adherence, to develop rules to flag potential non -adherence, and to determine the format and 
data to be included in the reports that will be transmitted from the CC to the MTQAC for review.  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  Study implementation  │ 53 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  In addition, they will lead the training of study ophthalmologists on the treatment protocol and 
serve as a resource for treatment -related questions throughout the trial.  
At the start of the trial, there will be intensive scrutiny.  Once a site has been certified and is open fo r enrollment, all available data on activity and treatment from the first two participants 
enrolled at that site will be reviewed by a member of the MTQAC.  The evaluations described below will be included as part of the intensive monitoring plan.  Thereafter, a combination of regularly scheduled and ad hoc reviews (e.g. , triggered by issues identified during site visits, 
monthly review of the study data, or other mechanisms) will be performed throughout the course of the study.   
 
A member of the MTQAC wil l review each report provided by the CC and determine whether 
corrective action (e.g. , retraining, site visit) is required. The entire MTQAC will hold quarterly 
conference calls to discuss patterns of deviations and to formulate recommendations regarding the need for additional training, monitoring or changes to the protocol.  Additional ad hoc 
meetings will be scheduled as necessary. MTQAC members will be included in site visits to 
clinics of concern, and the Study Chair will engage centers resistant or repeatedly inconsistent 
with activity assessment accuracy and/or protocol treatment implementation.  
 
10.2.2  Visual Function Quality Assurance Committee  
The Visual Function Quality Assurance Committee ( VFQAC ) monitors and certifies visual acuity 
and visual field examiners.  It is regularly present at site visits to the individual clinical centers and conducts training and certification of coordinators and other appropriate personnel at RG 
meetings.   In the ADVISE Trial, the visual function protocol and the VFQAC acti vities will 
conducted in the same manner we have used for other NEI -sponsored clinical trials.
21,22,23 Best-
corrected visual acuity score will be measured at  every study visi t under standardized lighting 
conditions by certified study examiners using logarithmic (ETDRS) visual acuity charts, according to the method described by Ferris, et al.
56 Peripheral visual fields in patients with 
birdshot chorioretinitis will be assessed by quantitative Goldmann perimetry18 or alternative 
evaluations of the peripheral field (e.g. , automated perimetry using both the SITA -fast 30-2 and 
the P60, a suprathreshold screening test of the peripheral field). 
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  54 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx  References  
1.   Jabs DA, Busingye J.  Approach to the diagnosis of the uveitides.  Am J Ophthalmol 
2013;156:228 -236.  PMCID: PMC3720682 
 2.   Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303 -308. PMID: 
2249907.  
 3.  Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and 
prevalence in a small urban community. Arch Ophthalmol 1962;68:502 -514. PM ID: 
13883604.  
 4.  Suttorp -Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature 
survey. Br J Ophthalmol 1996;80:844 -848. PMCID: PMC505625.  
 
5.  Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the 
Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491- 500; 
discussion 500. PMID: 15019324.  
 
6.  Jabs DA. Epidemiology of uveitis. Ophthalmic Epidemiol 2008;15:283 -4. PMID: 
18850463.  
 7.  de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, 
Barisani -Asenbauer T, LeHoang P, Lightman S. Understanding uveitis: the impact of 
research on visual outcomes. Prog Retin Eye Res 2011;30:452- 470. PMID: 21807112.  
 
8.  Research to Prevent Blindness. Annual Report 1993. In: Blindness RtP, ed. New York; 1993.  
 
9.  Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature 
(SUN) Working Group. Standardization of uveitis nomenclature for reporting clinic al 
data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509- 516. 
PMID: 16196117.  
 
10. Rothova A, Suttorp -van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency 
of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332 -336. PMCID: PMC505460.  
 
 
11. Raja SC, Jabs DA, Dunn JP, Fekrat S, Machan CH, Marsh MJ, Bressler NM. Pars 
planitis: clinical features and class II HLA associations. Ophthalmology 1999;106:594 -
599. PMID: 10080220.  
 
12. Donalds on MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: a 20- year study 
of incidence, clinical features, and outcomes. Am J Ophthalmol 2007;144:812- 817. 
PMID: 18036872.  
 
13. Jabs DA.  Treatment  of ocular  inflammation.  Ocul Immunol Inflamm 2004;12:163- 168. 
PMID: 15385193.   
  
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  55 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
14. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, 
Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D.  Guidelines  for the use of 
immunosuppressive drugs  in patients  with ocular  inflammatory  disorders:  
recommendations  of an expert  panel.  Am J Ophthalmol 2000;130:492- 513. PMID: 
11024423.   
 
15. The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow -up Study Research 
Group.  Association between long- lasting fluocinolone acetonide implant versus 
systemic anti -inflammatory therapy and visual acuity at 7 years among patients with 
intermediate, posterior, or panuveitis.  J Amer Med Assoc 2017;317:1993- 2005.  PMID:  
28477440.   
 
16. Goldberg NR, Lyu T, Moshier E, Jabs DA.  Success with single agent 
immunosuppression for multifocal choroidopathies.  Am J Ophthalmol 2014;158:1310 -
1317.  PMCID: 4254288.  
 
17. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH.  Birdshot  
retinochoroidopathy:  ocular  complications  and visual  impairment.  Am J Ophthalmol 
2005;140:45 -51. PMID: 16038650.   
 
18. Thorne JE, Jabs DA, Kedhar SR, Peters GB, Dunn JP.  Loss  of visual  field among  
patients  with birdshot  chorioretinopathy.  Am J Ophthalmol 2008;145:23 -28. PMID: 
17997394.   
 
19. Thorne JE, Wittenberg S, Jabs DA, Peters GB, Reed TL, Kedhar SR, Dunn 
JP. Multifocal  choroiditis  with panuveitis  incidence of ocular  complications  and of loss of 
visual  acuity.  Ophthalmology 2006;113:2310- 2316. PMID: 16996607.   
 
20. Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA.  Vogt-Koyanagi -Harada  
disease:  clinical outcomes.  Am J Ophthalmol 2005;140:674 -678. PMID: 16226518.   
 
21. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, 
Holbrook JT, Jabs DA, Sugar EA.  The Multicenter  Uveitis  Steroid Treatment  Trial:  
rationale,  design,  and baseline characteristics. Am J Ophthalmol 2010;149:550- 561. 
PMCID: PMC2975449.   
 
22. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.  Randomized 
comparison  of systemic anti-inflammatory  therapy  versus  fluocinolone acetonide implant  
for intermediate,  posterior,  and panuveitis:  the multicenter  uveitis  steroid  treatment  
trial. Ophthalmology 2011;118:1916 -1926. Erratum in: Ophthalmology 2012;119:212. 
PMCID: PMC3191365.   
 
23. The Multicenter Uveitis Steroid Treatment (MUST) Trial Follow -up Study Research 
Group. Benefits of systemic anti -inflammatory therapy versus fluocinolone acetonide 
intraocular implant for intermediate, posterior and panuveitis:  54 month results of The 
Multicenter Uveitis Steroid Treatment Trial (MUST) and Follow -up Study. Ophthalmology  
2015;122:1967 -75.  PMCID: PMC4581989.   
 
 
 
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  56 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
24. The Multicenter Uveitis Steroid Treatment (MUST) Trial Follow -up Study Research 
Group. Quality of life and risks associated with systemic anti -inflammatory therapy 
versus fluocinolone acetonide intraocular implant for intermediate, posterior or 
panuveitis:  54 month results of The Multicenter Uveitis Steroid Treatment Trial (MUST) 
and Follow -up Study. Ophthalmology  2015;122:1976- 86.  PMCID: PMC4581951.   
 
25. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaacmaz RO, Levy -Clarke GA, 
Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, 
Fitzgerald TD, Systemic Immunosuppression for Eye Disease (SITE) Research Group.  
Remission in intermediate uveitis: incidence and predictive factors.  Am J Ophthalmol 
2016;164:110 -117.  PMCID: PMC4811720.   
 
26. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM.  An evaluation of baseline risk 
factors  predicting  severity  in juvenile idiopathic  arthritis  associated  uveitis  and other  
chronic  anterior  uveitis  in early  childhood.  Br J Ophthalmol 2002;86:51 -56. PMCID: 
PMC1770968.   
 
27. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH.  Relapse  rate of uveitis  
post-methotrexate  treatment  in juvenile idiopathic  arthritis.  Am J Ophthalmol 
2011;151:217 -222. PMID: 21145533.   
 
28. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujan SS, Rosenbaum JT, 
Thorne JE, Foscter CS, Jabs DA, Levy -Clarke GA, Nussenblatt RB, Suhler EB. 
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148:500- 509.  
PMCID: PMC2753718.   
 
29. Gangaputra, S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy -Clarke GA, 
Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188 -2198.  PMCID: 
PMC3785935.
  
 
30. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy -Clarke GA, 
Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH.  
Mycophenolate mofetil for ocular inflammation.  Am J Ophthalmol 2010;149:423- 432.  
PMCID: PMC2826576.   
 
31. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, 
Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy -Clarke GA, Foster CS.  
Cyclosporine for ocular inflammatory diseases.  Ophthalmology 2010;117:576- 584.  
PMCID: PMC2830390.   
 
32. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, 
Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsm a JW.  Safety  of low dose glucocorticoid 
treatment  in rheumatoid arthritis:  published evidence and prospective trial data.  Ann 
Rheum Dis 2006;65:285 -293. PMCID: PMC1798053.   
 
33. del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A.  Glucocorticoid  
dose thresholds  associated with all-cause and cardiovascular  mortality  in rheumatoid 
arthritis.  Arthritis Rheumatol 2014;66:264- 272. PMID: 24504798.   
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  57 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
34. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, 
Jabs DA, Levy -Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS.  
Cyclophosphamide for ocular inflammatory diseases.  Ophthalmology 2010;117:356 -65.  
PMCID: PMC2819575   
 
35. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD.  
Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.  Arch 
Ophthalmol 2005;123:634- 641.  PMID: 15883282.   
 
36. Hogan AC, McAvoy CE, Dick AD, Lee RW.  Long -term efficacy and tolerance of 
tacrolimus for the treatment of uveitis.  Ophthalmology 2007: 114:1000- 1006.  PMID: 
17467532.   
 
37. Jaffe GJ,  Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani -Asenbauer 
T, Franco MD, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron 
M, Tari S, Suhler EB.    Adalimumab in patients with active non- infectious uveitis.  N 
Engl J Med 2016;375:932- 943. PMID: 27602665.  
 
38. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio 
C, Cimina L, Van Calster J, Carmez AA, Kwatra NV, Sone AP, Kron M, Tari S, Brezin 
AP.  Ad alimumab for the prevention of uveitic flare in patients with inactive non-
infectious uveitis controlled by corticosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo- controlled phase 3 trial.  Lancet 2016;388:1183- 92.  
PMID:27542302.
  
 
39. Diaz-Llopis M, Salom D, Garcia -de-Vicuna C, Cordero- Coma M, Ortega G, Ortego N, 
Suarez -Figueroa M, Rio- Pardo MJ, Fernandez -Cid C, Fondollosa A, Blanco R, Garcia-
Aparicio AM, Benitez -Del-Castillo JM, Olea JL, Arevalo JF.  Treatment of refractory 
uveitis  with adalimumab:  a prospective multicenter study of 131 patients.  
Ophthalmology 2012;119:1575- 1581.  PMID: 22525047.   
 
40. Kruh JN, Yang P, Suelves AM, Foster CS.  Infliximab for the treatment of refractory 
noninfectious uveitis: a study of 88 patients with long- term follow -up.  Ophthalmology 
2014;121:358 -364.  PMID: 24011995.   
 
41. Levy -Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.  Expert  
panel  recommendations  for the use of anti-tumor  necrosis  factor  biologic  agents  in 
patients  with ocular  inflammatory  disorders.  Ophthalmology 2014;121:785 -96. PMID: 
24359625.   
 
42. Taylor SR, Singh J, Menezo V, Wakefield D, McCluskey P, Lightman S.  Behçet 
disease: visual prognosis and factors influencing the development of visual loss.  Am J 
Ophthalmol 2011;152:1059- 1066.  PMID: 21872204.   
 
43. Kempen JH, Gangaputra S, Daniel E, Levy -Clarke GA, Nussenblatt RB, Rosenbaum JT, 
Suhler EB, Thorne JE, Foster CS, Jabs DA, Helzlsouer KJ.  Long- term risk of malignancy  
among  patients  treated  with immunosuppressive agents  for ocular  inflammation: a 
critical assessment  of the evidence.  Am J Ophthalmol 2008;146:802- 812. PMCID: 
PMC2614443.   
 
 
ADVISE  PROTOCOL 1.3 (12 OC T 2020)  References │  58 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
44. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kaçmaz RO, Pujari SS, 
Anzaar F, Foster CS, Helzlsouer KJ, Levy -Clarke GA, Nussenblatt RB, Liesegang T, 
Rosenbaum JT, Suhler EB.  Methods  for identifying long- term adverse effects  of 
treatment  in patients  with eye diseases:  the Systemic  Immunosuppressive Therapy  for 
Eye Diseases  (SITE)  Cohort  Study.  Ophthalmic Epidemiol 2008;15:47 -55. PMID: 
18300089.   
 
45. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, Helzlsouer KJ, 
Jabs DA, Kaçmaz RO, Levy -Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, 
Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE.  Overall  and cancer  related mortality  
among  patients  with ocular  inflamemation  treated  with immunosuppressive drugs:  
retrospective cohort  study.  BMJ 2009;339:b2480 PMCID: PMC2714688.   
 
46. Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D.  Malignancy  risk in patients  
with inflammatory  eye disease treated  with systemic immunosuppressive therapy:  a 
tertiary  referral  cohort  study.  Ophthalmology 2015;122:265 -273. PMID: 25312044.   
 
47. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, 
Medsger TA Jr,  Kwoh CK.  Effects  of cyclophosphamide on the development  of 
malignancy  and on long-term survival  of patients  with rheumatoid arthritis.  A 20-year 
followup study.  Arthritis Rheum 1995;38:1120 -1127. PMID: 7639809.   
 
48. Wolfe F, Michaud K.  The effect of methotrexate and anti -tumor necrosis factor therapy 
on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person 
years of observation.  Arthritis Rheum 2007;56:1433- 1439.  PMID: 17469100.   
 
49. Wolfe F, Michaud K.  Biologic treatment of rheumatoid arthritis and the risk of 
malignancy: analyses from a large US observational study.  Arthritis Rheum 
2007;56:2886 -95.  PMID: 17729297.   
 
50. Lopez Olivo MA, TayarJH, Martinez -Lopez JA, Pollono EN, Cueto JP, Gonzales -Crespo 
MR, Fulton S, Suarez -Almanzor ME.  Risk of malignancies in patients with rheumatoid 
arthritis treated with biologic therapy: a meta -analysis.  JAMA 2012;308:898- 908.  PMID: 
22948700.   
 
51. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA.  Juvenile idiopathic arthritis -
associated uveitis:  incidence of ocular complications and visual acuity loss.  Am J 
Ophthalmol 2007;143:840- 846. PMID: 17362866.   
 
52. Kacmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy -‘clarke GA, 
Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Foster CS, Systemic 
Immunosuppressive Therapy for Eye Disease Cohort Study Group.  Ocular inflammation 
in Behçet disease: incidence of ocular complications and of loss of visual acuity.  Am J 
Ophthalmol 2008;146:828- 836.  PMCID: PMC2617769.   
 
 
53. Gregory AC 2nd, Kempen JH, Daniel E, Kacmaz RO, Foster CS, Jabs DA, Levy -Clarke 
GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Systemic 
Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.  Risk 
factors for loss of visual acuity among patients with uveitis associated with juvenile 
idiopathic arthritis:  the Systemic Immunosuppressive Therapy for Eye Diseases Study.  
Ophthalmology 2013; 120:186- 192.  PMCID: PMC3536914.   
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  59 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
 
54. Lowder C, Belfort R Jr, Lightman S, Foster CS, robinson MR, Schifffman RM, Li XY, Cui 
H, Whitcup SM, Ozurdex HURON Study Group.  Dexamethasone intravitreal implant for 
noninfectious intermediate or posterior uveitis.  Arch Ophthalmol 2011;129:545- 553.  
PMID: 21220619.   
 
55. Yeh S, Forooghian F, Wong WT,  Faia LJ, Cukras C, Lew JC, Wroblewski K, Weichel 
ED, Meyerle CB, Sen HN, Chew EY, Nussenblatt RB.  Fundus autofluorescence 
imaging of the white dot syndromes.  Arch Ophthalmol 2010;128:46- 56. PMCID: 
PMC3025103.   
 
56. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I.  New visual  acuity  charts  for clinical 
research.  Am J Ophthalmol 1982;94:91- 96. PMID: 7091289.   
 
57. Ferris FL 3rd, Bailey I.  Standardizing  the measurement  of visual  acuity  for clinical 
research  studies:  Guidelines  from the Eye Care  Technology  Forum.  Ophthalmology 
1996;103:181 -182. PMID: 8628551.   
 
58. Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne 
JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial 
Research Group.  Fluorescein angiography versus optical coherence tomography for 
diagnosis of uveitic macular edema.  Ophthalmology 2013;120:1852- 1859. PMCID: 
PMC3758459.  
 
59. Domalpally A, Altaweel MM, Kempen JH, Myers D, Davis JL, Foster CS, Latkany P, 
Srivastava SK, Stawell RJ, Holbrook JT; MUST Trial Research Group.  Optical 
coherence tomography evaluation in the Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm 2012;20:443- 447. PMCID: PMC3824621.  
 
60. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, Thorne JE; 
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Identifying a 
clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.  Am J Ophthalmol 2011;152:1044- 1052. PMCID: PMC3223264.  
 
61. EuroQol Group.  EuroQol --a new facility for the measurement of health -related quality of 
life. Health Policy 1990;16:199- 208. PMID: 10109801.  
 
62. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53- 72. PMID: 
10158943.  
 
63. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost -effectiveness in health and 
medicine. New York: Oxford University Press: 1996.  
 
64. Jenkinson C, Wright L, Coulter A.  Criterion validity and reliability of the SF- 36 in a 
population sample.  Qual Life Res 1994;3:7 -12. PMID: 8142947.  
 
65. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake 
L. Validating the SF- 36 health survey questionnaire: new outcome measure for primary 
care.  BMJ 1992;305:160 -164. PMCID: PMC1883187.  
 
ADVISE PROTOCOL 1.3 (12 OCT 2020)  References │  60 
 
P:\Doc\MUST \ADVISE\ protocol \1.3 _12 Oct 2020\ ADVISE protocol 1.3_12 Oct 20.docx                                                                                                                                                         
66. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye 
Institute Visual Function Questionnaire Field Test Investigators. Development of the 25 -
item National Eye Institute Visual Function Questionnaire.  Arch Ophthalmol 
2001;119:1050 -1058. PMID: 11448327.  
 
67. Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, Rao NA, Sen HN, 
Sugar EA, Thorne JE, Wang RC, Holbrook JT; Multicenter Uveitis Steroid Treatment-
MUST Trial Research Group.  Associations among visual acuity and vision - and health-
related qual ity of life among patients in the multicenter uveitis steroid treatment 
trial. Invest Ophthalmol Vis Sci 2012;53:1169- 1176. PMCID: PMC3339901.  
 
68. Spaide RF, Goldberg N, Freund KB.  Redefining multifocal choroiditis and panuveitis 
and punctate inner choroidopathy through multimodal imaging.  Retina 2013;33:1315 -
1324.  PMID: 23584703.  
 
69. Kramer M, Priel E.  Fundus autofluorescence imaging in multifocal choroiditis: beyond 
the spots.  Ocular Immunol Inflamm 2013;22:349 -355. PMID: 24329681.  
 
70. Rathinam Sr, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E, Lee SM, 
Enanoria WT, Porce TC, Browne EN, Weinrib R, Acharya NR. A randomized clinical trial 
comparing methotrexate and mycophenolate mofetil for non- infectious uveitis.  
Ophthalmology . 2014;121:1863- 1870.  PMID: 24917273.  
 71. Galor A, Jabs DA, Leder HA, Kedhar SK, Dunn JP, Peters GB 3rd, Thorne JE.  
Comparison of antimetabolite drugs as corticosteroid- sparing therapy for noninfectious 
ocular inflammation.  Ophthalmology 2008;115:1826- 1832.  PMID :18579209.  
 
72 Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. Ann RheumDis 2016;75:795–
810.
 
 
73. Tomkins -Netzer O, Lightman S, Drye L, Kempen JH, Holland GN, Rao NA, Stawell RJ, 
Vitale A, Jabs DA for the Multicenter Uveitis Treatment Trial Research Group.  Outcome 
of treatment of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) 
Trial 2 -year results.  Ophthalmology 2015;122;2351- 2359.  PMCID: PMC4624003.  
 
74. Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, Acharya NR, 
Kempen JH, Jabs DA, The Multicenter Uveitis Steroid Treatment Trial Research Group.. 
Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone 
Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 2019; 
126(2):283- 295. PMC6348060
 
 
75. We inbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley, A, Neitzel SM, and 
Ward JW.  Recommendations for identification and public health management of persons with chronic hepatitis B virus  infection. MMWR 2008;57:RR -8:1-20
. 
 
76. Testing for HCV infect ion: an update of guidance for clinicians and labortorians. MMWR 
2013;62:362 -5. 
  